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ABSTRACT

THE ROLE OF CURCUMIN IN RESPONSE TO BPDE-INDUCED DNA DAMAGE IN
HUMAN LUNG EPITHELIAL CELLS
Erica Nicole Rogers
July 20, 2011

Long-term exposure to harmful carcinogens like benzo[a]pyrene (BaP) are linked
to lung cancer. Benzo[a]pyrene diol epoxide (BPDE), the ultimate carcinogen produced
by BaP bioactivation, is believed to play an important role in lung carcinogenesis. The
tumor suppressor protein is p53 signals cell cycle arrest, DNA repair, and apoptosis in
response to BPDE-induced damage. However, physiological exposure to BPDE fails to
activate p53. Although the bioactive principle of turmeric spice, curcumin, shows
promising effects against BPDE-induced carcinogenesis, its exact mode of action
remains unclear. Therefore the aim of this dissertation was to investigate whether
curcumin prevents BPDE-induced DNA damage by regulating p53-mediated cellular
responses in A549/LXSN (p53+) and A549/E6 (p53-) cells. I hypothesize that curcumin
may reduce BPDE-induced DNA damage by lowering the threshold of p53 activation,
thereby inducing p53-mediated mechanisms. Curcumin pretreatment reduced BPDEDNA adducts in a p53-dependent manner. However, p53-regulated proteins XPC and
DDB2 did not change with curcumin pretreatment and p53-expression. Curcumin
pretreatment did not change the overall repair rate in p53+ cells. Curcumin pretreatment,
p53-expression, and BPDE exposure did not significantly change glutathione-S-
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transferase (GST) levels or activity as well as glutathione (GSH) levels. Curcumin
increased levels of p53, phosphorylated p53 at Ser15 (P-p53S15), and CDKN1A, but
decreased phosphorylated retinoblastoma at Ser807/811 (P-pRbS807/811) in p53+ cells
with lower BPDE exposure. Curcumin and BPDE increased and decreased PpRbS807/811, respectively, in p53- cells. BPDE induced S phase arrest in both cell
lines. P53+ curcumin pretreated cells escaped S phase arrest earlier with 300 nM BPDE
in contrast to BPDE treatment alone. Yet, curcumin did not change S phase arrest in
p53+ cells treated with 50 or 100 nM BPDE. P53- cells did not escape S phase arrest 24
h after low (50 and 100 nM) BPDE exposures; p53- curcumin pretreated cells entered S
phase arrest earlier. Phosphorylated CHK1 Ser345 (pCHKS345) levels, an indicator of S
phase arrest, was higher in p53- cells than p53+ cells; curcumin increased
pCHK1 Ser345. Curcumin also induced apoptosis earlier in p53- cells exposed to 300nM
BPDE. Therefore, this dissertation shows that curcumin prevents BPDE-induced DNA
damage by activating a host of mechanisms independent of p53 expression.

vi

TABLE OF CONTENTS

PAGE

iii

DEDICATION
ACKNOWLEDGMENTS
ABSTRACT
LIST OF FIGURES

iv
v-vi
ix-xi

Chapter I: INTRODUCTION

1-18

Chapter II: CURCUMIN PRETREATMENT REDUCED BPDE-INDUCED
DNA DAMAGE IN A P53-DEPEDNENT MANNER
INTRODUCTION

19-22

MATERIALS AND METHODS

23-32

RESULTS

33-49

DISCUSSION

50-55

Chapter III: CURCUMIN AFFECTS CELL CYCLE ARREST AND
APOPTOSIS IN HUMAN LUNG EPITHELIAL CELLS IN RESPONSE
TO BPDE-INDUCED DNA DAMAGE
INTRODUCTION

56-58

MATERIALS AND METHODS

59-60

RESULTS

61-71

DISCUSSION

72-74

Chapter IV: GENERAL DISCUSSION

75-77

Chapter V: FUTURE DIRECTIONS

78-79

REFERENCES

80-93

APPENDIX: LIST OF ABBREVIATIONS

94-96
vii

CURRICULUM VITAE

97-100

viii

LIST OF FIGURES
FIGURE

PAGE

1. PATHWAYS OF B(A)P METABOLISM

4

2. BIOACTIVATION OF BENZO(A)PYRENE TO THE ULTIMATE
CARCI NOG EN 7 R,aS-DI HYDROXY-9S, 1OR-EPOXY-7 ,a,9, 10TETRAHYDROBENZO(A)PYRENE (BPDE)

5

3. TWO STEREOISOMERIC FORMS OF BPDE-DNA ADDUCTS

6

4. ACTIVATED P53 SIGNALS A NUMBER OF RESPONSES

a

5. ACTIVATED P53 SIGNALS G1/S CHECKPOINT

9

6. NUCLEOTIDE EXCISION REPAIR PATHWAYS

11

7. STRUCTURE OF THE CURCUMINOIDS: CURCUMIN,
DEMETHOXYCURCUMIN AND BISDEMETHOXYCURCUMIN

a.

14

CHEMICAL STRUCTURES OF MAJOR METABOLITES OF CURCUMIN IN
RODENTS AND HUMANS

16

9. ACTIVATED P53 SIGNALS THE UP-REGULATION OF DNA
DAMAGE RECOGNITION PROTEINS XPC AND DDB2 IN
RESPONSE TO DNA DAMAGE

22

10. OVERALL EXPERIMENTAL DESIGN FOR ALL STUDIES

24

11. IMMUNOSLOT BLOT ANALYSIS OF BPDE-DNA ADDUCTS
IMMEDIATELY AFTER 1 HOUR BPDE TREATMENT

34

12. WESTERN BLOT ANALYSIS OF P53 AND XPC IMMEDIATELY
(0 H) AND 24 H AFTER BPDE TREATMENT

ix

36

13. RELATIVE XPC LEVELS IMMEDIATELY (0 H) AND 24 H AFTER BPDE
TREATMENT

37

14. WESTERN BLOT ANALYSIS OF P53 AND DDB2 LEVELS
IMMEDIATELY (0 H) AND 24 H AFTER BPDE TREATMENT

38

15. RELATIVE DDB2 LEVELS IMMEDIATELY (0 H) AND 24 H AFTER BPDE
TREATMENT

39

16. WESTERN BLOT ANALYSIS OF P53 AND DDB2 LEVELS
24 HOURS AFTER DNA DAMAGE IN DIFFERENT CELL TYPES
WITH DIFFERENT TREATMENTS

40

17. IMMUNOSLOT BLOT ANALYSIS OF BPDE-DNA ADDUCTS
REMAINING IMMEDIATELY (0). 6 AND 24 H AFTER BPDE
TREATMENT

42

18. GSTA AND GSTM ARE NOT PRESENT IN A549 CELLS

45

19. EFFECTS OF CURCUMIN PRETREATMENT AND P53
EXPRESSION ON GST PROTEIN LEVELS AND ACTIVITY

46

20. EFFECTS OF CURCUMIN PRETREATMENT AND P53
EXPRESSION ON GST PROTEIN LEVELS AND ACTIVITY

47

21. EFFECTS OF CURCUMIN PRETREATMENT AND P53
EXPRESSION ON THE ACTIVITY ON CELLULAR-REDUCED
GSH LEVELS

48

22. POSSIBLE MECHANISM BY WHICH CURCUMIN REDUCES
BPDE-DNA ADDUCTS

53

23. STRUCTURES OF CURCUMIN AND ELLAGIC ACID

54

24. CURCUMIN ENHANCES P53 AND CDKN1A INDUCTION
IN RESPONSE TO BPDE-INDUCED DAMAGE.

x

62

25. P53-EXPRESSING A549/LSXN CELLS TRANSIENTLY ARREST
IN S-PHASE IN RESPONSE TO BPDE-INDUCED DAMAGE.

64

26. P53-DEFICIENT A549/E6 CELLS ARREST IN S PHASE, BUT
NEVER ESCAPE WITH LOWER BPDE CONCENTRATIONS.

65

27. LEVELS OF CYCLIN A AND E IN RESPONSE TO CURCUMIN
PRETREATMENT AND EXPOSURE TO BPDE

67

28. P-CHK1SER345IS ACTIVATED IN P53-DEFICIENT CELLS
AFTER BPDE TREATMENT

68

29. CURCUMIN ENHANCES APOPTOSIS IN APOPTOSIS IN A549/E6
CELLS IN RESPONSE TO 300 NM BPDE.

xi

70

CHAPTER I

GENERAL INTRODUCTION
Overview
Lung cancer remains one of the most common causes of cancer-related deaths
in America [1-4]. Despite major surgical and therapeutic improvements in the treatment
and management of this disease, these methods are unsuccessful in reducing the
overall mortality rate of lung cancer. As a result, alternative methods are needed to
control this disease. Because lung cancer is primarily caused by long-term exposure to
environmental carcinogens, much research has been devoted to discovering better ways
to inhibit the process of carcinogenesis. Chemoprevention is a rapidly growing area
focused on preventing, hampering, arresting or reversing the process of carcinogenesis.
The naturally-occurring agent, curcumin, the major bioactive constituent in turmeric, has
shown promising activity against cancer. Traditionally known for its uses in Indian
cooking and medicine, curcumin has shown promising effects in combating the
carcinogenic activity of chemicals such as benzo(a)pyrene (BaP) [5-7].
BaP is a well known carcinogenic compound present in tobacco smoke,
charbroiled food, and coal tar [8-10]. The highly reactive and mutagenic metabolite of
BaP, 7R,8S-dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE), is
believed to play an important role in lung carcinogenesis by damaging DNA [11 ;12]. The
tumor suppressor protein p53 is known to respond to DNA damage by signaling cell
cycle arrest, DNA repair, and apoptosis [13-15]. In addition, BPDE can be inactivated by
the glutathione (GSH) detoxification pathway [16;17]. Although p53 is activated in
1

response to BPDE-induced DNA damage, physiological exposure to BPDE is relatively
low and fails to activate p53. As a result, failure to activate p53 in response to BPDEinduced DNA damage leads to an increase likelihood of mutations. An increase in
mutations may ultimately lead to cancer. This project focuses on how curcumin may play
a significant role in decreasing the carcinogenic activity of BPDE. Specifically, this
dissertation focuses on whether curcumin reduces BPDE-induced DNA damage by
lowering the threshold of p53 activation and subsequent DNA repair and cell cycle
pathways.
Chapter two of this dissertation examines whether curcumin modulates DNA
repair and BPDE detoxification pathways in a p53-dependent manner. Data show that
curcumin significantly lowered BPDE-DNA adducts only in p53-expressing cells.
However, curcumin did not change the overall repair rate of BPDE-induced DNA
damage in a p53-dependent manner. In addition, curcumin and p53-expression did not
playa role in the GSH detoxification pathway.
Chapter three of this dissertation investigated if curcumin affects the regulation of
p53 and p53-mediated cell cycle progression in response to BPDE-induced DNA
damage. Curcumin changed cell cycle arrest mechanisms in p53+ and p53- cells in
response to BPDE-induced DNA damage.
Lung Cancer
Lung cancer is one of the most common cancers worldwide, accounting for 1.3
million deaths annually [18]. In the United States, lung cancer is the leading cause of
cancer-related deaths among men and women [19]. It is estimated that exposure to
environmental carcinogens causes 90% of all reported lung cancer cases.
Environmental carcinogens are commonly present in polluted air and water [2023] , tobacco products and their smoke [24;25], charbroiled food and smoke [26-28], and
occupational environments [29;30]. One of the most widespread environmental

2

carcinogens is polycyclic aromatic hydrocarbons (PAHs) [10;31 ;32].
Polycyclic Aromatic Hydrocarbons
PAHs are a major class of carcinogenic chemicals formed by incomplete
combustion of organic matter [9]. Typically, these carcinogens are metabolically
activated in the body by the cytochrome P450 (CYP) system into electrophilic derivatives
that covalently bind to DNA [8;33]. The binding of PAHs to DNA forms bulky adducts that
can lead to mismatched base pairing. If PAH-DNA adducts are not removed, mutations
may result, which ultimately can lead to cancer [34].
Benzo(alpyrene (BaPl
Benzo(a)pyrene (BaP) is a well characterized PAH that can be converted into a
number of metabolites [35-38] (Figure 1). BaP is characterized by a bay region which
possesses a rigid, planar structure. It is well established that 7 R,8S-dihydroxy-9S, 1ORepoxy-7,8,9, 10-tetrahydrobenzo(a)pyrene (BPDE) is the most reactive carcinogen
formed by BaP bioactivation [36] (Figure 2). BPDE can bind to nucleophilic centers of
macromolecules. However, BPDE preferentially reacts with the exocyclic amino groups
of guanine to form bulky adducts on DNA. Thus, the major BPDE-DNA adducts are
2

formed with guanine bases (N -BPDE-dG). BPDE binds to guanine either with the
pyrene system within the minor groove (trans) or "intercalated" into the DNA (cis) [31]
(Figure 3). In mammalian cells, trans-BPDE-DNA adducts are more mutagenic than cisBPDE-DNA adducts [37;39;40]. Commonly if these adducts are bypassed or not
repaired, adducted guanine pairs with adenine instead of cytosine during DNA
replication. Consequently, during the next cell division cycle adenine, the wrong base,
will pair with thymine. As a result, a point mutation will occur known as a G to T
transversion. BPDE-induced G to T transversions are known to occur in key genes
related to tumor development, including proto-oncogenes of the ras family as well as
tumor suppressor genes such as p53 [10]. As a result, detrimental effects such as
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Figure 1. Pathways of B(a)P metabolism. Adapted from "Impact of Cellular Metabolism
on the Biological Effects of Benzo[a]pyrene and Related Hydrocarbons," by Kimberly
Miller, 2001, Drug Metabolism Reviews, 33 (1), p. 1-35.
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Figure 2. Bioactivation of benzo(a)pyrene to the ultimate carcinogen 7R,8S-dihydroxy9S,1 OR-epoxy-7 ,8,9, 1O-tetrahydrobenzo(a)pyrene (BPDE). BPDE primarily reacts with

the exocyclic amino group of guanine. Adapted from "Application of biologically based
computer modeling to simple or complex mixtures," by K.H . Liao, 2002, Environ. Health

Perspect. 110 Suppl 6, p. 957-963.

5

Cis-adducts

Figure 3. Two stereoisomeric forms of BPDE-DNA adducts. BPDE binds to guanine
either with the pyrene system within the minor groove (trans) or "intercalated" into the
DNA (cis). Black=DNA backbone; green= guanine; and red= N2-BPDE-dG. Adapted
from "Origins of conformational differences between cis- and trans-DNA adducts derived
from enantiomeric anti-benzo[a]pyrene diol epoxides ," by X.M. Xie , 1999, Chern. Res.
Toxicol. 12(7), p. 597-609.
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cytotoxicity and inhibition of DNA synthesis can occur which disrupt the integrity of
genetic material.
P53 responses to DNA damage
Several cellular responses to DNA damage help to prevent mutations from
occurring. One of the most common cellular responses to BPDE-induced DNA damage
is the stabilization and activation of the tumor suppressor protein p53 [15]. In unstressed
cells, p53 transactivation is inhibited by the E3 ubiquitin ligase, human double minute-2
(HDM2). HDM2 regulates p53 activity in two ways: (1) it binds and blocks the
transactivation domain of p53; and (2) it conjugates ubiquitin molecules onto p53, which
signals p53 degradation by the proteasome [41]. In response to DNA damage, p53 is
phosphorylated in its transactivation domain and dissociates from HDM2 [41-43].
Phosphorylation of p53 increases its stability and function. Stabilization and additional
posttranslational modifications subsequently activate p53. Activation of p53 up-regulates
cell cycle arrest, DNA repair, or apoptosis, depending on the type and duration of DNA
damage [13;44;45] (Figure 4).
P53 and Cell Cycle Arrest
Activated p53 inhibits the interaction between cyclins and cyclin dependent
kinases (CDKs), which signals cell cycle arrest [46-49]. Activated p53 signals G1 or G2
arrest. G1 arrest is important because it prevents replication of damaged DNA. P53mediated transcriptional activation of CDK inhibitor CDKN1 A (sometimes termed
p21wAF1/CIP1) commonly induces G1 arrest [50;51] (Figure 5). CDKN1A prevents
interactions between cyclin E-CDK2 and cyclin D-CDK4/6 thereby preventing the
phosphorylation of retinoblastoma protein (pRb). As a result, pRb remains bound to and
inactivates E2F1. E2F1 is one of several transcription factors responsible for the
regulation of genes required for S phase progression. P53 can also activate several
downstream targets responsible for G2 arrest, including CDKN1 A, GADD45, and

7

/
Cell Cycle Arrest

Apoptosis
DNA repair

Figure 4. Activated p53 signals a number of responses. In unstressed cells, p53
remains bound to and inactivated by HDM2 via degradation. In response to DNA
damage p53 undergoes stabilization and activation to signal cell cycle arrest, DNA
repair, and apoptosis.
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Figure 5. Activated p53 signals G1/S checkpoint. During G1 progression , cyclins and
CDKs are allowed to interact with each other. The interactions between the cyclin-CDK
complexes phosphorylate retinoblastoma (Rb) . As a result, Rb becomes
hyperphosphorylated. Hyperphosphorylation of Rb releases E2F1 which results
activation of genes requ ired for S phase entry. In response to DNA damage, p53 is
stabilized and activated to up-regulate CDKN1A, a CDK inhibitor. Up-regulation of
CDKN1A inhibits the bind ing of cyclins to CDKs , thus leaving Rb hypophosphorylated.
Hypophosphorylated Rb remains bound to E2F1 and inhibits cell cycle progression .

9

14-3-30. Transcriptional activation of these genes simultaneously inhibits the kinase
activity of CDK1 with cyclin B (cyclin B-CDK1). Cyclin B-CDK1 complex is necessary for
entry into the M phase. In cases where DNA cannot be repaired, p53 initiates apoptosis.
P53 and Global Genomic Repair
Besides regulating cell cycle arrest and apoptosis, p53 plays a critical role in
nucleotide excision repair (NER) [52]. NER is the major DNA repair pathway for the
removal of adducts induced by UV light and bulky chemicals such as BPDE [53-56]. The
NER system involves five steps: (1) DNA damage recognition, (2) multi-protein excision
complex assembly, (3) excision of the damage, (4) gap filling with correct DNA, and (5)
sealing of thenew DNA with the original undamaged portion (Figure 6). NER is divided
into two distinct subpathways: transcription coupled repair (TCR) and global genomic
repair (GGR). In TCR, RNA polymerase II recognizes damage on the transcribed DNA
strands of active genes. On the other hand, GGR protein complexes DNA damage
binding protein 1/2 (DDB1/DDB2) and Xerderma pigmentosum group C/human UV
excision repair protein RAD23 homolog B (XPC/HR23B) recognize damage in both
nontranscribed and transcribed genes. GGR effectively removes bulky adducts formed
by BPDE [52].
Further, p53 mediates the basal and inducible expression of DNA damage
recognition genes XPC and DDB2 [57-60]. While activated p53 up-regulates a host of
cellular protective mechanisms, environmental exposure to BPDE is relatively low (S1 00
nM). As a result, p53 remains inactive, thereby preventing its ability to act as a protective
mechanism against DNA damage.
BPDE Detoxification
In addition to removing DNA damage, several other mechanisms protect DNA by
converting BPDE to inactive forms. These mechanisms include: BPDE hydrolysis to
tetrols and keto diols, and BPDE conjugation with glutathione (GSH). Conversion of
10
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BPDE to inactive forms prevents the interaction between BPDE and DNA. Conjugation
of BPDE with GSH is the most important detoxifying mechanism against BPDE.
Glutathione-(S)- transferases (GSTs) catalyze the reaction between BPDE and GSH to
produce inert, hydrophilic compounds [61-63] (Figure 1). Additionally a possible
correlation between GST and p53 expression has been suggested [64;65]. For example,
it was found that expression of GSTP did not significantly modify the life span and the
tumor spectrum in p53 knockout mice. Thus, these results suggested that the influence
of p53 on tumor development may mask the possible role of GSTP in response to
carcinogen-induced DNA damage. Overall, however, it is not fully understood whether
the GSH system influences cellular mechanisms such as p53 in response to chemical
insults such as BPDE.
Curcumin as a Chemopreventive Agent
Techniques such as surgical resection, radiation ablation, and chemotherapy
currently manage and control lung cancer. However, in most cases, lung cancer is not
detected until it has metastasized to other parts of the body [1]. As a result, the overall
survival rate for lung cancer is fairly low [66]. In turn, many researchers are investigating
alternative approaches to control the onset of lung cancer. Because this disease is
primarily caused by long-term exposure to environmental carcinogens, much cancer
research is devoted to discovering innovative ways to inhibit carcinogenesis. One of the
current approaches includes the use of dietary constituents including curcumin [67;68].
Chemical Structure. Properties. and Biotransformation of Curcumin
Curcumin (diferuloylmethane) is a major constituent of turmeric powder which is
extracted from the rhizomes of the plant Curcuma longa Linn (Figure 7) [69]. Curcumin is
a polyphenolic compound with a l3-diketone moiety [70]. It contains two ferulic acid
molecules linked via a methylene bridge at the C atom of the carboxyl group. Many
studies speculate that the biological activity of curcumin resides in either the double

12

bonds of the alkene part of the molecule, the hydroxyl groups of the benzene rings,
and/or the central ~-diketone moiety. Commercial curcumin contains curcumin I (-77%),
demethoxycurcumin (-17%), bisdemethoxycurcumin (-3%) as its major components
[71 ;72]. Curcumin is relatively insoluble in water, but dissolves in acetone,
dimethylsulfoxide, and ethanol [72]. Curcumin is unstable in neutral basic pH
environmental. Curcumin instability at neutral and basic pH leads to degradation of
curcumin within 30 minutes to trans-6-(4'-hydroxyphenyl)-2, 4,-dioxo-5-hexenal, ferulic
acid (4-hydroxy-3-methoxycinnamic acid), ferulonyl methane (4-hydroxy-3methoxycinnamonyl-methane) and vanillin [73;74].The amount of vanillin increased with
incubation time. Curcumin in the presence of fetal calf serum or human blood, or
addition of antioxidants such as ascorbic acid, N-acetylcysteine or glutathione,
completely prevent the degradation of curcumin in culture media or phosphate buffer
above pH 7. Curcumin is more stable in cell culture media containing 10% fetal calf
serum or in human blood, with less than 20% decomposition within 1 hour compared to
90% within 30 minutes in serum-free medium [75-78]. After incubation for 8 hours, about
50% of curcumin still remained in serum-containing medium.
The absorption, metabolism, and tissue distribution of curcumin in rodents and
humans is well characterized. In rats, 75% of a 1 g/kg dose of curcumin was excreted in
the feces. Negligible amounts of curcumin were found in rats' urine [79]. In another
study, 60% of oral curcumin administered to rats was absorbed, while glucuronide and
sulfate conjugates were found in urine. When the bioavailability of curcumin was studied
from this same group, [3H]-radiolabelling showed that majority of an oral dose of
curcumin was excreted in the feces [75]. Consequently, only one-third of curcumin was
excreted in an unmetabolized form. Intravenous and intraperitoneal administration of
curcumin in rodents resulted in large quantitied of curcumin and metabolites in bile,
which were characterized mainly as tetrathydrocurcumin and
13
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Figure 7. Structure of the curcuminoids curcumin, demethoxycurcumin and
bisdemethoxycurcumin. Adapted from "Curcumin: A review of anti-cancer properties and
therapeutic activity in head and neck squamous cell carcinoma,"
By R. Wilken, 2011. Mo/ecu/arCancer2011 p 10:12.
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hexahydrocurcumin glucuronides (Figure 8). This study suggested that curcumin
undergoes transformation during absorption via the intestine and possibly is subjected to
entero-hepatic recirculation- [77]. Another study of intraperitoneal curcumin administered
to mice suggested that curcumin was first biotransformed to dihydrocurcumin and
tetrahydrocurcumin, and that these compounds were subsequently converted to
monoglucuronide conjugates [78]. Oral curcumin administered to rats using high
pressure liquid chromatography (HPLC) demonstrated small amounts of curcumin in
plasma with higher levels of curcumin glucuronide and curcumin sulfate in plasma, and
small quantities of hexahydrocurcumin, hexahydrocurcuminol and hexahydrocurcumin
glucuronide. Metabolism of curcumin in humans, however, is poorly understood.
Preclinical work in human hepatocytes, liver, and gut microsomes suggested that
metabolic reduction of curcumin occurred very rapidly. Additionally, co-administration of
piperine along with curcumin, in rats, increased systemic bioavailability of curcumin as
much as 154% [72]. Piperine is known as a constituent of pepper vine, piper nigrum, hot
jalapeno peppers, and peppercorns. To be brief, curcumin exhibits low oral
bioavailability in rodents and may undergo intestinal metabolism; absorbed curcumin
undergoes rapid first-pass metabolism and excretion in the bile. Consequently,
transformation of curcumin to curcumin-glucuronoside, dihydrocurcumin-glucuronoside,
THC-glucuronoside, and THC has been implicated to play critical roles in curcumininduced biological activites [16;80;81].
Curcumin and SPDE
Widely known for its uses in Indian cooking and traditional Chinese medicine,
curcumin has shown promising activity against many diseases such as lung cancer [82].
Specifically, several models have shown that curcumin impedes the carcinogenic activity
for many chemicals including SaP. Curcumin, for example, prevented SaP-induced
tumorigenesis in mice by increasing the detoxification of SPDE in liver [5;7]. Additionally,
15
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Polasa et al. demonstrated curcumin prevented BPDE-induced strand breaks in
peripheral blood lymphocytes [6].
Although curcumin has been shown to inhibit DNA damage [7;83], there is no
sound evidence for how curcumin influences p53-mediated cell cycle progression and
DNA repair mechanisms in response to BPDE-induced DNA damage. Therefore, the
focus of this dissertation is on determining how BPDE-induced DNA damage is affected
by p53 expression. Additionally, this dissertation determined how curcumin may playa
role in decreasing the carcinogenic activity of BPDE through modulating p53 expression.
Thus, modifications of p53 as well as p53-mediated cell cycle arrest and DNA repair
mechanisms by curcumin in response to BPDE were examined. It was also determined
whether curcumin enhances GST activity as well as GST and GSH levels in a p53dependent manner as an alternative pathway to reduce the carcinogenic effect of BPDE.
Overall this work reveals a novel mechanism by which curcumin signals p53-mediated
cell cycle arrest and DNA repair mechanisms.
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Objective
Determine whether pretreatment with curcumin inhibits BPDE-induced DNA
damage by lowering the threshold of p53 activation, thereby inducing DNA repair and
cell cycle arrest at lower BPDE exposures. To test this hypothesis, human lung cells with
and without p53 expression (A549/LXSN and A549/E6) will be used as a model system,
to achieve the following aims:
Specific Aims
1. Determine the effects and mechanism of curcumin on the regulation of p53 and its
mediation of cell cycle progression in lung cells treated with low dose BPDE.
2. Determine if curcumin modulates the efficiency of DNA repair in a p53-dependent
manner.
3. Investigate the role of curcumin in the induction of p53-dependent DNA repair
proteins.
4. Determine whether curcumin influences glutathione (GSH) system in a p53dependent manner.
Hypothesis
Curcumin pretreatment reduces BPDE-induced DNA damage by lowering the
threshold of p53 activation and subsequent p53-mediated cell cycle arrest and DNA
repair pathways.
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CHAPTER II

CURCUMIN PRETREATMENT REDUCED BPDE-INDUCED DNA DAMAGE IN A P53DEPENDENT MANNER
Introduction
Curcumin (diferuloylmethane) is an active constituent in turmeric derived from the
rhizome plant Curcuma longa Linn (Figure 7) [84;85]. Traditionally, curcumin is known
for its used in medicine and cooking in the Eastern World. Preclinical studies have
shown that curcumin possesses promising activity as a chemopreventive agent against
many cancers. It is thought that curcumin blocks tumor initiation and proliferation
induced by DNA damaging agents such as bioactivated polycyclic aromatic
hydrocarbons (PAHs) [83;86;87].
PAHs are ubiquitous environmental pollutants implicated in lung carcinogenesis
(Rubin 2001; Rybicki et al. 2006). PAHs are commonly present in exhaust fumes [8],
tobacco smoke [88], barbequed food [20;28], and occupational environments [89].
Senzo(a)pyrene (SaP) is a well known PAH that is metabolized into a number of
derivatives. The metabolite 7 R,8S-dihydroxy-9S, 1OR-epoxy-7,8,9, 10tetrahydrobenzo(a)pyrene (SPDE) is defined as the most reactive and ultimate
carcinogen formed by SaP bioactivation [90]. SPDE is produced by a series of
cyctochrome P450-dependent monoxygenase reactions from SaP (Figure 2) [91]. In the
first step, SaP is oxidized primarily by CYP1A1/1 S1 to a SaP-7,8-epoxide [92]. Next,
epoxide hydrolases catalyze the conversion of the 7,8-epoxide to (+)-SaP-trans-7,8dihydrodiol. Lastly, the (+)-SaP- trans-7,8-dihydrodiol metabolite is further oxidized by
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CYP1A1/1 B1 into the ultimate carcinogen BPDE. BPDE is characterized by a bay region
which promotes its highly reactive electrophilic activity. BPDE is known to interact with
the N2 or N7 position of guanine. When BPDE binds to the N7 position of guanine, very
7
unstable N7-BPDE-dG adducts are produced. As a result, these N -BPDE-dG adducts
are readily hydrolyzed to form apurinic sites. However, BPDE predominantly damages
DNA by binding to the N2 position of guanine [93]. If these DNA adducts are not
removed, mutations may result which eventually lead to cancer. Efficient detoxification of
BPDE and removal of DNA damage are suggested mechanisms which may lead to
lower incidence of BPDE-induced mutations [79;94].
Repair of bulky adduct DNA damage mainly occurs through nucleotide excision
repair (NER). NER involves five steps: (1) damage recognition, (2) multi-protein excision
complex assembly, (3) damage excision, (4) gap filling, and (5) ligation (Figure 6). NER
is divided into two distinct subpathways based on how DNA damage is recognized:
transcription coupled repair (TCR) or global genomic repair (GGR). TCR specializes in
recognizing and eliminating damage on the transcribed strand of active genes. GGR, on
the other hand, recognizes and removes damage from the entire genome. GGR is
necessary to remove BPDE-DNA adducts [95;96]. A number of studies show that
expression of the tumor suppressor protein p53 is required for the GGR process.
Namely, functional p53 is important to mediate the basal and inducible expression of
DNA damage recognition proteins XPC and DDB2 (Figure 9) [59;97-99]. Curcumin has
been shown to decrease BaP-derived DNA adduct formation as well as induce p53 [100102]. However, it is unclear whether curcumin reduces BPDE-DNA adducts by activating
p53-mediated DNA repair mechanisms such as GGR.
Besides the NER pathway removing BPDE-DNA adducts, other mechanisms can
prevent BPDE-DNA adducts from forming. Detoxification systems, which inactive
BPDE, offer an alternative mechanism against the formation of BPDE-DNA adducts. The
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glutathione (GSH) pathway is the major system which inactivates BPDE [61-63]. The
GSH pathway is composed of detoxification enzymes, known as glutathione-Stransferases (GSTs), which catalyze the transfer of GSH to xenobiotic agents like BPDE.
As a result, nontoxic, water soluble, inactive compounds are produced and excreted.
The GST multi-gene family is made up of seven classes in humans: Alpha, Beta, Zeta,
Pi, Theta, Omega, and Mu. Among the seven classes, GST-Mu (GSTM), GST-Alpha
(GSTA) and GST-Pi (GSTP) have been proposed as key enzymes for BPDE inactivation
[94;103-105]. Contradictory studies have suggested curcumin can induce as well as
inhibit GST activity. For example, curcumin was a potent inhibitor of GST activity in 1chloro-2, 4-dintirobenzene (CDNB) treated human melanoma cells [106]. Singh et al.
also examined the interaction of GST activity with curcumin [5]. In mice, curcumin
decreased BaP-induced forestomach tumorigenesis by significantly increasing hepatic
GST activity. In turn, increased GST activity prevents potential interactions of BPDE with
DNA. Additionally, GSTs and p53 accumulation are suggested in to protective
mechanisms against PAH-induced DNA damage [107-111]. However little is known
whether curcumin affects the GSH system in a p53-dependent manner.
In the present study, I investigated whether curcumin reduces BPDE-induced
DNA damage in lung epithelial cells by enhancing p53 expression and subsequent p53mediated DNA repair mechanisms. Specifically, I determined the role curcumin plays in
the expression of p53 and p53-regulated proteins DDB2 and XPC in response to BPDE.
Furthermore, I examined whether curcumin affects BPDE detoxification via the
glutathione pathway and whether this effect was p53-dependent. Overall this study
provides evidence that curcumin reduces BPDE-DNA adducts in a p53-dependent
manner.
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DNA damage recognition
prOrins
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Figure 9. Activated p53 signals the up-regulation of DNA damage recognition proteins
XPC and DDB2 in response to DNA damage.
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Materials and methods

Cells and Cell cultures
Two isogenic human A549 lung cancer cell lines were used in this study.
A549/LXSN (p53+) and A549/E6 (p53-) cells were transduced with either an empty
retrovirus (A549/LXSN) or a retrovirus expressing human papillomavirus (HPV)-16 E6
oncoprotein (A549/E6). These cell lines were kind gifts from Dr. Jeffery Schwartz,
University of Washington, Seattle, WA. The expression of HPV-16 E6 in A549/E6 cells
signals ubiquitin mediated degradation of p53. These cell lines were grown as
monolayers in Dulbecco's Modified Eagle's Medium (DMEM): Ham's F12 media
supplemented with 1% Penicillin/Streptomycin (Pen-Strep) (Fisher Scientific, Cat#
ICN1670049), 1% HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer
pH 7.4 (Fisher Scientific, Cat#ICN1688449), and 10% fetal bovine serum (FBS)
(ThermoFisher Scientific, Cat# SH30070.01) at 37

ac in 5% CO 2 • HeLa cells, which also

express HPV16 E6 oncoprotein, were grown as monolayer in DMEM supplemented with
10% FBS and 1% Pen-Strep. HeLa cells were used to confirm the expression of DDB2.

Curcumin treatments
Curcumin was a kind gift from Dr. Ramesh Gupta, University of Louisville,
Louisville, KY. The main stock of curcumin was prepared by dissolution in dimethyl
sulfoxide (DMSO; Fisher Scientific, Pittsburg, PAl at 80 mM and stored at -20

ac.

Working stocks were made at 2.5 mM and diluted to 2.5 ~M in cell culture media. Cell
lines were treated with 2.5 ~M curcumin or DMSO for 24 hours prior to BPDE treatment
(Figure 10).

23

Plate A549/LXSN (p53+) and A549/E6 (p53-) cells
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1

Harvest cells at 0 - 72 h
Figure 10. Overall experimental design for all studies. AS49/LXSN (pS3+) and AS49/E6
(pS3-) cells were used in this study. AS49 cells were plated and incubated for 24 hours
at 3rC to ensure attachment to plate. The following day, AS49 cells were pretreated
with

a (OMSO) or 2.S I-lM curcumin for 24 hours. Next, the media was removed , and

cells were washed twice in PBS. Then cells were refed with fresh media and exposed to

a (THF) , so, 100, or 300 nM for 1 hat 3rC. After which , cells were washed twice in

1x

PBS and either immediately harvested or refed with fresh media for up to 72 hours. Cells
were harvested at different time points for experiments.
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BPDE treatments
Benzo(a)pyrene- 7R, 8S-dihydrodiol-9S,1 OR-epoxide (±), anti (BPDE) was
purchased from the National Cancer Institute Chemical Carcinogen Repository (Midwest
Research Institute, Kansas City, MO). Tetrahydrofuran (THF; Fisher Scientific, Pittsburg,
PA) was used to prepare stocks of BPDE. The main stock was prepared at 10 mM
BPDE and stored in a dessicator at -20°C. Hydrolysis of BPDE was checked prior to
usage [112]. A BPDE mix containing 2 IJL of 10 mM BPDE, 48IJL THF, 50 IJL 2mercaptoethanol solution (2 mM 2-mercaptoethanol, 0.1 N NaOH), 900 IJL of double
distilled water was prepared to check the fraction of BPDE hydrolyzed. A blank mix was
also made which contained 2 IJL of THF, 50 IJL of 2-mercaptoethanol solution, and 900
IJL of double distilled water. Absorbances at 348 and 343 nm (A348 and A343 ,
respectively) were collected and the fraction unhydrolyzed was calculated as followed:

Fraction unhydrolyzed= (A34s1A343) x 0.529 + 0.104

The unhydrolyzed main stock was calculated as the fraction unhydrolyzed
against the main stock. Therefore, if the fraction unhydrolyzed was 0.8, the main stock
(10 mM BPDE) was assumed to be 8 mM unhydrolyzed. Working stocks were prepared
with fresh THF at concentrations 100 times the desired concentration. Working stocks
were diluted to 1X in cell culture medium. Cells were treated with fresh media containing
50, 100, or 300 nM BPDE. Cells were incubated at 37°C for 1 hour and washed twice
with calcium-and magneSium-free phosphate-buffered saline (136 mM NaCI, 8.1 mM
Na2HP04, 1.5 mM KH 2P04 pH 7.4) (PBS). Cells were either immediately (0 hour)
collected or refed with fresh media and incubated at 37°C until collection (Figure 10).
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uv treatment
6

A549 and HeLa cells were plated in 15 cm dishes (1 x 10 cells/ dish). Cells were
incubated for 16 hours to attach to the plate. Each dish was washed with 5 mL of
2
PBS and cells overlaid with 2 mL PBS. Cells were UV-irradiated with 0 or 20 J/m UVC
at a fluence of 0.5 J/m2/s. After irradiation, PBS was drained, and the cells refed with 25
mL of fresh media and incubated until collection.

Cisplatin treatment
A549 and HeLa cells were seeded in 15 cm dishes (1 x 106 cells/ dish). Cells
were incubated overnight to attach to the plate. The next day, stock solutions of cisplatin
(1 mg/mL in 1X PBS) were freshly prepared the day of treatment and filter sterilized
(0.22 IJm) prior to use. Cisplatin was dissolved in media to yield a final concentration of 5
IJM. Cells were washed with 5 mL of PBS and refed with 25 mL of media containing
cisplatin for 24 hours. After 24 hours, cells were drained of media, washed with 5 mL
PBS, and harvested.

Genomic DNA isolation
A549 cells were seeded into 15 cm dishes (1 x 106 cells/ dish) and incubated for
24 hours. The next day cells were treated with or without 2.51JM curcumin for 24 hours.
The following day, the media was removed and fresh media added to each dish. Then
the cells were treated with 0-300 nM BPDE for 1 hour. BPDE was prepared as described
in the "BPDE treatments" section of this chapter. After BPDE exposure, cells were either
lysed immediately or refed and incubated 6 or 24 hours. Cells were collected at 0
(immediately after 1 hour BPDE treatment), 6 and 24 hours. During collection, the cells
were washed with 5 mL PBS and lysed with DNA lysis buffer (0.5 M Tris-HCI pH 8.0, 20
mM ethylene diamine tetraacetic acid disodium salt (Na2EDTA), 10 mM NaCI, 1%
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sodium dodecyl sulfate (SDS), 0.5 mg/mL proteinase K). Lysates were incubated
overnight at 37°C for proteinase K digestion. Lysates were mixed with 1/4 volume
saturated NaCI solution and centrifuged (30 minutes, 500 x

g, room temperature) to

pellet undigested protein, cellular debris and SDS precipitate. Supernatants were
collected in a fresh tube, mixed with 2 volumes 96% ethanol, and inverted several times.
Precipitated nucleic acids were collected on a glass hook, rinsed in 70% ethanol, briefly
dried to remove excess ethanol, and resuspended in 1X Tris-EDTA (TE) buffer (10 mM
Tris-HCI pH 7.4, 1 mM Na2EDTA). RNA was digested by the addition of fresh 100 I-Ig/mL
heat-treated RNase A (40 mg/mL) and incubation at 3rC for 3 hours. The solution was
then mixed gently with 115 volume 11 M ammonium acetate (pH 6.7) and 2 volumes cold
96% ethanol. DNA precipitated overnight and was recovered the following day. Next, the
DNA was rinsed in 70% ethanol, briefly dried, and resuspended in 1X TE buffer. DNA
was quantified by A 260 and purity determined by A26ofA280 ratio. DNA was stored at -20°C
until ready for use.

DNA adduct determination by immunoslot blot assay
BPDE-DNA adducts were determined using the method of Venkatachalam et al.
[79]. Briefly 6 or 0.75 I-Ig of A549/LXSN or A549/E6 genomic DNA, respectively was
bound to nitrocellulose BA 85 membrane (Schleicher and Schuell, Keene, NH) using a
Minifold II slot blot apparatus (Schleicher and Schuell, Keene, NH). BPDE-DNA adducts
. were detected using BP1 primary antibody developed against anti-BPDE modified DNA
(a kind gift from Altaf A. Wani, Ohio State University, Columbus, OH) (1 :2000) followed
by goat anti-rabbit IgG alkaline phosphatase (AP)-Iabeled secondary antibody (1: 10,000)
(Zymed). Signal intensities were visualized using enhanced chemifluorescence substrate
(ECF, GE Healthcare, Piscataway, NJ). The intensity of each band was determined
using a Molecular Dynamics Storm 860 (Minneapolis, MN) in blue fluorescence mode,
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and quantitated by ImageQuant software. BPOE-ONA adduct levels and the rates of
repair were calculated by comparing the band intensities of DNA from BPOE treated
cells against DNA from untreated samples and normalized to values to 0 hour samples.

Western blot analysis
A549 cells were seeded into 10 em dishes (750,000 cells/dish) and incubated for
24 hours to attach to the dish. The cells were treated with or without 2.5 IJM curcumin for
24 hours. The following day, the cells were treated with 0-300 nM BPOE for 1 hour after
aspirating the media and washing with 1 mL PBS. After BPOE exposure, cells were
either lysed immediately or refed and incubated 24 hours. During collection, total protein
Iysates from whole cells were prepared after BPOE treatment with protein lysis buffer
solution (10 mM Tris-HCI pH 7.4,1 mM Na2EOTA 0.1 % SOS, 0.18 mg/mL
phenylmethylsulphonylfluoride (PMSF». The Iysates were incubated at 37°C for 5
minutes. The Iysates were sonicated (to make the Iysates less viscous) and centrifuged
at 13,000 x gfor 30 minutes, 4°C to precipitate cell debris. Total protein content from
supernatants was determined by Bradford assay (Biorad, Hercules, CA) using bovine
serum albumin (BSA) as a standard. Samples were denatured with loading buffer (50
mM Tris-HCI pH 6.8,10% glycerol, 2% SOS, 1% 2-mercaptoethanol, 12.5 mM
Na2EOTA, 0.02% bromophenol blue) and heated at 90°C for 2 minutes. Twenty
micrograms of total cellular protein were resolved by electrophoresis in a 10% SOSpolyacrylamide gel with a 1 em stacking gel at 120 V for about 1.5 hours. Proteins were
electro-transferred to a nitrocellulose membrane (100 V, 1 hour, 4°C). Nitrocellulose
membranes were stained with 1X Ponceau S stain (Fisher Scientific, Pittsburg, PA) for
10 minutes to ensure complete electro-transfer, adequate separation of proteins, and
equal protein load. After a digital photograph (Kodak Photography) was taken of the
Ponceau stained membrane, the membrane was destained for 5 minutes in Tris-buffered
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saline Tween-20 (100 mM Tris-HCI pH 7.5,150 mM NaCI, 0.1% Tween 20) (TBST) and
blocked with 5% milk (Nestle, Solon, OH) in TBST for 1 hour at room temperature.
Membranes were incubated with the following primary antibodies and dilutions as
described by the manufacturer: anti-p53 00-1 mouse monoclonal antibody (NeoMarkers,
Cat# MS-187-P) (1:1000); anti-phospho-p53 Ser15 mouse polyclonal antibody (Cell
Signaling Technology, Cat#9284) (1 :500); anti-DDB2 mouse monoclonal antibody
(Abcam, Cat# 2246C4a) (1 :50); anti-X PC mouse monoclonal antibody (Santa Cruz,
Cat#sc-30156, St. louis, MO) (1:1000); anti-GSTP goat polyclonal antibody (Detroit
R&D, Cat# GST ANTIR3, Detroit, MI) (1:10,000); anti-GSTA goat polyclonal antibody
(Detroit R&D, Cat# GST ANTI 1 , Detroit, MI) (1:10,000); anti-GSTM goat polyclonal
antibody (Detroit R&D, Cat# GST ANTI 2 , Detroit, MI) (1:10,000); GAPDH (Abcam,
Cat# ab9484) (1:10.000) or j3-actin (Abcam, Cat# ab8227) (1:10,000) served as the
loading controls and j3-actin mouse monoclonal antibody (Abcam, Cat# 8227)
(1: 10,000). The membranes were washed with TBST three times for 10 minutes each.
Detection of GAPDH and j3-actin served as loading control. Blots probed with anti-p53,
anti-phospho-p53 Ser 15, anti-DDB2, anti-XPC, and anti-j3-actin primary antibodies were
incubated with rabbit anti-mouse IgG conjugated to horseradish peroxidase (HRP) (Cell
Signaling Technologies, Cat #7076) (1 :2,000 in 5% milk in TBST) for detection. AntiGSTP primary antibody was detected by goat anti-rabbit IgG conjugated to HRP (Cell
Signaling Technologies, Cat #7074) (1:10,000 in 5% milk in TBST). Signal intensities
were visualized using enhanced chemiluminescence substrate plus (ECl plus, GE
Healthcare, Piscataway, NJ, Cat#RPN2132). Detection and quantitation of signal
intensities was achieved using a Molecular Dynamics Storm 860 in blue fluorescence
mode. Signal intensities were analyzed by ImageQuant.
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GST colorimetric assay
A549 cells were seeded into 10 cm dishes (750,000 cells/dish) and incubated for
24 hours. The cells were treated with or without 2.5 IJM curcumin for 24 hours. The
following day, the cells were exposed to 0-300 nM BPOE for 1 hour after removing the
media and washing with 1 mL PBS. Whole cells were immediately scraped in cold
phosphate-buffer solution (25 mM sucrose, 50 mM potassium phosphate, 1 mM
Na2EOTA, pH 6.5) after BPOE treatment. Cells were sonicated on ice and centrifuged at
14,000 rpm for 30 minutes, 4°C. Supernatants were collected and stored at -80°C up to
a month. Total protein content from supernatants was determined by Bradford assay
using BSA as a standard. Supernatants (25-50 IJg of protein) were mixed with 100 JlL of
10 mM L-glutathione (GSH; Sigma Aldrich, St. Louis, MO) in phosphate-buffer solution
(pH 6.5) in a cuvette. Enough phosphate-buffer solution was added to bring the final
volume in the cuvette up to 1 mL. Absorbance was read at 340 nm for 1 min in a Varian
Cary UV Spectrophotometer (Agilent Technologies, Palo Alto, CA) to determine
background activity. Ten microliters of 1-chloro-2,4-dintrobenzene (CONB, Cat# 237329,
Santa Cruz, St. Louis, MO) in ethanol was added and absorbance read for an additional
3 minutes to gather enzyme kinetics data. GST activity was calculated using the
following formula:

[~Abs/min

(sample) - ~Abs/min (background»)
Am

X

mg protein added

where Am , the extinction coefficient for GS-ONB, equals 0.0096 IJmor1cm- 1 • GST activity
is expressed as nanomoles per minute per microgram of protein (nmollmin/lJg protein).
GST activity was normalized to A549/E6 cells treated only with BPOE.
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Cellular GSH content
A549 cells were seeded into 10 cm dishes (7.5 x 105 cells/dish) and incubated for
24 hours. The cells were treated with or without 2.5 IJM curcumin for 24 hours. Curcumin
at 2.5 IJM was prepared as described above. The following day, the cells were exposed
to 0-300 nM BPDE for 1 hour after removing the media and washing with 1 mL PBS.
BPDE was prepared as described above. Whole cells were harvested by scraping in 1
mL cold PBS, collected into pre-chilled microfuge tubes, and centrifuged (1000 x g, 5
minutes, 4°C). Pellets were resuspended in 1 mL fresh ice-cold extraction buffer (0.1 %
Triton, 0.6% sulfosalicylic acid in 0.1 M potassium phosphate with 10 mM Na2EDTA, pH
7.5), sonicated on ice 2-3 minutes, and freeze-thawed twice. After the second freezethaw cycle, cells were centrifuged (3000 x g, 4 minutes, 4°C) and supernatant collected
into microfuge tubes. Pellets were dissolved in 0.2 M NaOH and total protein content
from this solution was determined by Bradford assay using BSA as a standard.
Samples were assayed for glutathione using L-glutathione (Sigma-Aldrich, St.
Louis, MO) as a standard [113]. A fresh 0.1 M potassium phosphate stock solution

'

(KPE) was prepared by mixing 16 mL of solution A with 84 mL of solution B (solution A:
Add 3.4 g KH 2P04 to 250 mL dH 20; solution B: 8.5 g K2HP04 to 500 mL dH 20). A 0.1 M
phosphate-EDTA (KPE) buffer was prepared by adjusting the 0.1 M potassium
phosphate stock solution to pH 7.5 and adding 0.327 g Na2EDTA was added. Next, a
GSH stock solution was prepared by dissolving 1 mg of GSH in 1 mL KPE. The GSH
stock solution was diluted 1: 100 to make a 10 IJg/mL working solution. Then a 26.4
nM/mL GSH standard solution was prepared by mixing 800 IJL of GSH working solution
with 200 IJL of KPE. The 26.4 nM/mL solution served as the highest GSH standard
solution. Twofold serial dilutions were prepared until a 0.413 nM/mL GSH standard
solution was achieved. GSH standards were kept on ice. DTNB (1.68 mM), j3-NADPH
(0.79mM), and Glutathione reductase (GR) (6.68 UlmL) solutions were also prepared by
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dissolving compound in KPE. To assay, 20 j..IL of each standard and each sample in
triplicate were added to a microtiter plate at room temperature. Equal volumes of DTNB
and GR solutions were mixed together (DTNB:GR). Then, 120 j..IL of the DTNB:GR
solution was added to each well of the plate. The plate sat for about 30 seconds to allow
the DNTB/GR solution to convert all GSSG in my samples to GSH. Sixty microliters of

13-

NADPH was added to each well of the plate. An absorbance at 412 nm for the samples
was read immediately at 15-30 intervals for 5 minutes. The total GSH concentration of
my samples was determined by the GSH standard curve. GSH was expressed as
nanomoles per milligram total cellular protein (nmol/min/j..lg of protein). Samples were
normalized to A549/E6 cells treated with respective concentrations of BPDE only.

Statistical analysis

All statistical analysis was measured using GraphPad Prizm (version 5.01). All
data are expressed as means ± standard deviations (STDEV) of at least three
independent experiments. BPDE-DNA adducts immediately after 1 hour BPDE
treatment, XPC, DDB2, GSTP protein levels, GST activity, and GSH levels were
analyzed by one-way analysis of variance (ANOVA) followed by Bonferroni's comparison
test. Analysis of the overall repair rate was analyzed by two-way ANOVA. P < 0.05 was
considered statistically significant.
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Results

Curcumin pretreatment significantly lowers BPDE-induced DNA damage in p53expressing cells
BPDE attaches to guanine bases of DNA to cause damage. P53 accumulates in
response to DNA damage. Separate studies show that curcumin inhibits chemicalinduced damage and up-regulates p53 [7;85;114-116]. It is, however, unclear whether
curcumin prevents BPDE-induced DNA damage by modulating p53 expression.
Immunoslot blot assay was used to determine the effect of curcumin on BPDE-DNA
adduct levels in isogenic cells expressing and not expressing p53 (Figure 11).
A549/LXSN (p53+) and A549/E6 (p53-) cells were incubated with or without curcumin for
24 hours, followed by 50, 100, or 300 nM BPDE. Cells were immediately harvested and
lysed after 1 hour BPDE treatment. Relative BPDE-DNA adducts were assessed and
compared on separate membranes based on BPDE concentration used. BPDE-DNA
adduct levels were significantly lower in LXSN than E6 cells at all three BPDE exposures
(Figure 11). Furthermore, curcumin pretreatment significantly lowered BPDE-DNA
adduct levels in LXSN cells at all BPDE exposures. Curcumin pretreatment did not affect
BPDE-DNA adduct levels in E6 cells. Thus these results show that curcumin reduces
BPDE-DNA adducts in a p53-dependent manner.

XPC and DDB2 are not regulated by p53-expression in A549 cells
Bulky helix distorting DNA lesions induced by BPDE are removed by the GGR
system [117]. DNA damage recognition proteins XPC and DDB2 function in the GGR
system to recognize bulky DNA adducts [96;118]. It is well established that basal and
inducible expression of XPC and DDB2 are regulated by p53 [59;119]. Little is known
about whether curcumin affects the expression of XPC and DDB2. I therefore used
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Figure 11. Immunoslot blot analysis of BPDE-DNA adducts immediately after 1 hour
BPDE treatment. A549/LXSN (p53+) cells and A549/E6 (p53-) were treated with DMSO
(0

~M)

or 2.5

~M

curcumin for 24 h followed by 50 (A), 100 (B), or 300 nM BPDE (C) for

1 hour. Cells were harvested immediately after BPDE exposure. Genomic DNA was
collected and BPDE-DNA adduct levels determined by immunoslot blot assay. The
difference between DNA from BPDE treated cells and DNA untreated cells were
calculated. The values from triplicate samples were averaged and normaljzed to BPDEDNA adducts in A549/E6 cells with respective BPDE only treatments (0 ~M curcumin).
Data are presented as mean

± STDEV of BPDE-DNA adducts

in three independent

experiments. Analysis of data was performed using a one-way ANOVA followed by
Bonferroni's comparison test. #P<0.05

VS.

LXSN cells with corresponding curcumin and

BPDE treatment. * P<0.05 compares LXSN cells treated with BPDE alone against
curcumin pretreated LXSN cells exposed to respective BPDE.
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Western blot analysis to investigate how curcumin affects p53 as well as p53-regulated
DNA damage recognition proteins XPC and DDB2 (Figures 12 through 15). In Figures
12 and 14, A549 cells were pretreated with or without curcumin for 24 hours, and then
exposed to 0, 50, 100, or 300 nM BPDE for 1 hour. Protein extracts were collected from
lysed cells either immediately (0 h) or 24 hours after BPDE treatment. P53 was present
in LXSN (p53+), but not E6 (p53-) cells (Figures 12 and 14). P53 was increased 24
hours after BPDE treatment only in A549/LXSN cells. Curcumin pretreatment further
increased p53 in p53+ cells. XPC was present in both cell lines (Figure 12). However,
the level of XPC differed depending on curcumin pretreatment, p53 expression, and
time. Overall, XPC was higher in A549/LXSN cells (Figure 12A) than A549/E6 cells
(Figure 12B). XPC was not induced immediately after 1 hour BPDE exposure in either
cell line. XPC was increased in a concentration-dependent manner 24 hours after BPDE
treatment in p53+ cells (Figure 12A). Yet, XPC was absent 24 hours with or without
BPDE treatment in p53- cells (Figure 12B). Curcumin pretreatment further increased
XPC in A549/LXSN cells. Curcumin pretreatment also increased XPC levels in A549/E6
immediately after 1 hour BPDE treatment. Therefore these results indicate that XPC is
not regulated by p53 expression in A549 cells. Curcumin pretreatment however changes
the expression of XPC in response to BPDE-induced DNA damage.
DDB2 was also present in both cell lines; however neither curcumin nor BPDE
changed DDB2 levels (Figure 14 and 15). To investigate further whether DDB2 is
regulated by p53, DDB2 was examined after DNA damage in different cell types with
different DNA damaging agents (Figure 14). A549/LXSN (p53+), A549/E6 (p53-), and
HeLa cells were exposed to either 300 nM BPDE for 1 hour (BPDE), UV (20 J/m 2) (UV),
or 5 IJM cisplatin
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Figure 12. Western blot analysis of p53 and XPC immediately (0 h) and 24 h after BPDE
treatment. A549/LXSN (p53+) (A) and A549/E6 (B) cells were incubated with 0 or 2.5 IJM
curcumin for 24 h. Cells were then exposed to 0, 50, 100 or 300 nM BPDE for 1 hour
and washed twice with Ca2+-/Mg 2+-free PBS. Next, cells were either immediately
harvested (0 h) or incubated at 37°C for 24 h in fresh media, and then harvested. Whole
ceillysates were collected from harvested cells. Twenty micrograms of protein were
resolved on 10% SDS-PAGE for Western blot analysis. GAPDH served as loading
control. Data shown are representative of three independent experiments.
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Figure 13. Relative XPC levels immediately (0 h) and 24 h after BPDE treatment.
AS49/LXSN (pS3+) (top panels) and AS49/E6 (bottom panels) cells were incubated with

o or 2.S IJM curcumin for 24 h. Cells were then exposed to 0, SO, 100 or 300 nM BPDE
for 1 hour and washed twice with Ca 2+-/Mg 2+-free PBS. Next, cells were either
immediately harvested (0 h) or incubated at 3rC for 24 h in fresh media, and then
harvested. Whole celllysates were collected from harvested cells. Twenty micrograms of
protein were resolved on 10% SDS-PAGE for Western blot analysis. The ratio between
XPC and GAPDH was computed from Western Blots. Analysis of data was performed
using a one-way ANOVA followed by Bonferroni's comparison test. *P<O.OS compared to

o IJM curcumin. #P<O.OS compared to 0 nM BPDE.
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Figure 14. Western blot analysis of p53 and DOB2 levels immediately (0 h) and 24 h
after BPOE treatment. A549/LXSN (p53+) (A) and A549/E6 (B) cells were incubated with

o or 2.5 IJM curcumin for 24 h. Cells were then exposed to 0, 50, 100 or 300 nM BPDE
for 1 hour and washed twice with Ca2+-/Mg 2+-free PBS. Next, cells were either
immediately harvested (0 h) or incubated at 37°C for 24 h in fresh media, and then
harvested. Whole cell Iysates were collected from harvested cells. Twenty micrograms of
protein were resolved on 10% SOS-PAGE for Western blot analysis. l3-actin served as
loading control. Data shown are representative of three independent experiments.
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Figure 15. Relative DDB2 levels immediately (0 h) and 24 h after BPDE treatment.
A549/LXSN (p53+) (top panles) and A549/E6 (bottom panels) cells were incubated with

o or 2.5 ~M curcumin for 24 h. Cells were then exposed to 0,50,100 or 300 nM BPDE
for 1 hour and washed twice with Ca 2+-/Mg 2+-free PBS. Next, cells were either
immediately harvested (0 h) or incubated at 3rC for 24 h in fresh media, and then
harvested. Whole ceillysates were collected from harvested cells. Twenty micrograms of
protein were resolved on 10% SDS-PAGE for Western blot analysis. The ratio between
XPC and GAPDH was computed from Western Blots. Analysis of data was performed
using a one-way ANOVA followed by Bonferroni's comparison test.
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Figure 16. Western blot analysis of p53 and DDB2 levels 24 hours after DNA damage in
different cell types with different treatments. A549/LXSN (p53+), A549/E6 (p53-), and
HeLa cells were exposed to either 300 nM BPDE for 1 hour (BPDE), UV (20 J/m 2 ) (UV),
or 5 IJM cisplatin (CSP) for 24 hours. Cells were then washed twice with Ca 2+-/Mg 2+-free
PBS after treatments and incubated at 37°C for an additional 24 hours in fresh media.
Whole cell Iysates were collected from harvested cells after 24 hours. Twenty
micrograms of protein were resolved on 10% SDS-PAGE for Western blot analysis.
actin serves as loading control. Data shown are representative of three independent
experiments.
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(CSP) for 24 hours. Cells were then washed twice with Ca 2+-/Mg 2+-free PBS after
treatments and incubated at 37°C for an additional 24 hours in fresh media. Whole cell
Iysates were collected from harvested cells after 24 hours. HeLa cells are cervical
carcinoma cells containing HPV-16. HPV16 produces an active E6 which targets p53
degradation. Therefore I hypothesized that DDB2 should be present, but not be induced,
in HeLa cells. Figure 16 reveals that p53 was induced by all 3 agents in A549/LXSN
(p53+) cells. P53 was also present, but not induced with in response to DNA damaging
agents, in A549/E6 (p53-) and HeLa (p53-) cells. With the exception of BPDE treated
HeLa cells, p53 was not induced by the DNA damaging agents in the p53-deficient cell
lines. DDB2 was present in all cell types. In A549/LXSN cells, DDB2 increased with
BPDE and cisplatin treatments. In A549/E6 cells, all DNA damaging agents decreased
levels of DDB2 compared to untreated control. DDB2 was present in HeLa cells, but not
induced, by treatment with DNA damaging agents.

Curcumin does not change the repair rate in A549 cells
To determine whether curcumin alters the overall repair rate of BPDE-induced
DNA damage, the relative amounts of BPDE-DNA adducts remaining after BPDE
exposure were measured over time using immunoslot blot assay (Figure 14). Cells were
pretreated with or without curcumin for 24 h, exposed to 50 (Figures 17A and 170), 100
(Figures 17B and 17E) or 300 nM (Figures 17C and 17F) BPDE, and DNA collected at 0
(immediately after 1 hour BPDE treatment), 6, and 24 hours. The relative amount of
BPDE-DNA adducts remaining in A549/LXSN (p53+) cells decreased with increasing
time for all three treatments (Figures 17A-17C). Curcumin pretreatment did not change
the overall removal rate of BPDE adducts in A549/LXSN cells. The relative BPDE-DNA
adduct levels in A549/E6 (p53-) cells treated increased over time (Figures 17D-17E).
The relative amount of BPDE-DNA adducts significantly increased over time with
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Figure 17. Immunoslot blot analysis of BPDE-DNA adducts remaining immediately (0),6
and 24 h after BPDE treatment. AS49/LXSN (pS3+) (A through C) and AS49/E6 (pS3-) (D
through F) cells were treated with 0 (closed triangles) or 2.S IJM curcumin (open circles)
for 24 h. Cells were treated with SO (A and D), 100 (B and E) or 300 nM (C and F) BPDE
for 1 hour and washed twice with Ca 2+-/Mg 2+-free PBS. Cells were either immediately
harvested (0 h) or incubated with fresh media for an additional 6 or 24 h. Genomic DNA
was purified from harvested cells and subjected to immunoslot blot assay. BPDE-DNA
adducts in genomic DNA were measured using anti-BPDE DNA specific antibodies. The
difference between DNA from BPDE treated cells and DNA untreated cells were
calculated. The values from triplicate samples were averaged and normalized to values
for 0 hour repair samples for each BPDE exposure. Data presented as means ± STDEV
of relative amount of BPDE-DNA adducts in three independent experiments. A two-way
ANOVA test was used to compare curcumin vs. control group. Any significant changes
were noted as *p<O.OS.
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curcumin pretreatment in A549/E6 cells exposed to 50 nM BPDE. On the other hand,
curcumin pretreatment did not change the relative amount of BPDE-DNA adduct levels
in A549/E6 cells exposed to 100 and 300 nM BPDE (Figure 170). Overall these results
suggest that removal of BPDE-DNA adducts depends on p53-expression. Yet, curcumin
does not influence the rate of BPDE-DNA adduct removal.

Curcumin influence on GSH system
It is unclear whether curcumin changes the activity of GST in a p53-dependent
manner. GST-alpha (GSTA), GST-mu (GSTM), and GST-pi (GST) are known to
inactivate BPDE [36;64;107;120]. Because I found in Figures 11 and 17 that curcumin
prevented BPDE-DNA adduct formation only in p53+ cells, yet had no profound
influence on the DNA repair rate, I determined whether GSH and GST may playa role
in eliminating BPDE-DNA adduct. Therefore, I pretreated cells with or without curcumin
for 24 hours, followed by either 0 (THF; BPDE control solvent), 50, 100, or 300 nM
BPDE for 1 hour and immediately harvested the cells (0 h) to analyze GSTA, GSTM,
and GSTP (Figures 18 through 19). Also, I examined whether p53 expression, curcumin
pretreatment, and BPDE exposure change GST activity and GSH levels (Figures 20 and
21). GSTP levels (Figures 15A and 15B) were not changed by p53-expression,
curcumin pretreatment, or BPDE exposure. GSTA and GSTM were examined, but were
not present in p53-expressing or non-expressing (Figure 18). P53 expression did not
influence the relative amount of GST activity (Figure 19). Curcumin lowered GST activity
in both cell lines exposed to 50 nM BPDE. P53 expression and curcumin pretreatment
affected GSH levels in cells exposed to 50 and 100 nM BPDE (Figure 20). When cells
were treated with 50 nM BPDE, GSH levels in A549/LXSN cells were significantly higher
than A549/E6 cells. Also, curcumin significantly increased GSH levels in A549/E6 cells
treated with 100 nM BPDE in contrast to A549/E6 cells exposed to 100 nM BPDE only.
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Figure 18. GSTA and GSTM are not present in A549 cells . Murine liver cells (M),
untreated A549/LXSN (p53+; L) and A549/E6 (p53-; E) proteins were separated on 10%
SDS-PAGE. Samples were analyzed to evaluate the presence of GST-alpha (GSTA)
and GST-mu (GSTM). Mouse liver cells served as a positive control for GSTA and
GSTM expression. Ponceau stain served as the loading control.
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Figure 19. Effects of curcumin pretreatment and p53 expression on GST protein levels
and activity. A549/LXSN (p53+) and A549/E6 cells were pretreated with 0 or 2.5 IJM
curcumin for 24 hours. Then cells were exposed to 0, 50, 100 or 300 nM 8PDE for 1
hour, harvested immediately (0 h), then sonicated and homogenized and analyzed (A)
and quantitated by Western blot (8). Errors bars for GSTP protein levels indicate means

± STEDV of GST protein levels against Ponceau stain (loading control) in two
independent experiments.

45

IIIIIillll

0 IJM Curcumin E6 (p53-)

. . 2.5 IJM Curcumin E6 (p53-)

~ 0 IJM Curcumin LXSN (p53+)
~ 2.5 uM Curcumin LXSN (p53+)
'2

50 nM

300 nM

100 nM

~ 140

140

140

E'120

120

~ 100

100

.s,., 60

~ 80

80
60

120
100
80
60

~

40

40

20

20

Q.

~

40
ti)
20
(9

Curcumin 0 ~.l..I..U-_
+
(2.5IJM):
E6 (p53-)

OL-U~-

O'----"-~

+
LXSN (p53+)

E6 (p53-)

+
LXSN (p53+)

+

+
E6 (p53-)

LXSN (p53+)

Figure 20. Effects of curcumin pretreatment and pS3 expression on GST protein levels
and activity. AS49/LXSN (pS3+) and AS49/E6 (pS3-) cells were pretreated with 0 or 2.S

IJM curcumin for 24 hours. Then cells were exposed to 0, SO, 100 or 300 nM BPDE for 1
hour and harvested immediately (0 h). AS49 cells were sonicated, homogenized for GST
activity assay. AS49/E6 cells exposed only to BPDE were expressed as 100% for each
BPDE exposure. All others were compared to AS49/E6 BPDE treated cells. Data are
represented as means

± STDEV of relative
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experiments. * denotes p<O.OS vs. compares with respective AS49 cells pretreated with
and without curcumin and BPDE exposure.
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Overall, GSH levels were not significantly altered by p53 expression, curcumin
pretreatment, or BPDE exposure in these cells (Figure 21). Therefore, these results
indicate that the GSH system does not playa significant role in reducing BPDE-DNA
adducts.
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Figure 21. Effects of curcumin pretreatment and pS3 expression on the activity on
cellular-reduced GSH levels. AS49/LXSN (pS3+) and AS49/E6 cells were pretreated with

o ~M (DMSO) or 2.S ~M curcumin for 24 h. Then cells were exposed to 0, SO,

100 or

300 nM BPDE for 1 hour, harvested immediately (0 h), then sonicated and homogenized
for measurement of the cellular-reduced GSH levels. AS49/E6 cells exposed only to
BPDE were expressed as 100% for each BPDE exposure. All others were compared to
AS49/E6 BPDE treated cells. Data are represented as means ± STDEV of relative GSH
levels from three independent experiments. * denotes p<O.OS vs. E6 cells pretreated with
DMSO (curcumin control) and BPDE
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Discussion
SaP is an environmental carcinogen that is metabolized into the ultimate
carcinogen SPDE. SPDE poses a health risk to humans because it can bind and
damage DNA. If SPDE-DNA adducts are not repaired, then resulting mutations may
accumulate and ultimately lead to cancer. Many reports show that activated p53 signals
DNA repair in response to high concentrations of SaP (2:100 nM) [13; 15; 117].
Environmental exposure to SaP, however, is relatively low which results in low SPDE
from metabolized SaP. Thus, the physiological concentration of SPDE is much lower
than those used in most in vitro studies; as a result, p53 remains inactive. Studies show
that curcumin reduces SPDE-induced DNA damage, yet its exact mechanism of action
remains unclear. Specifically, it is unclear whether curcumin lowers SPDE-DNA adducts
by influencing p53-mediated DNA repair mechanisms.
Several separate contradictory reports show that p53 expression and curcumin
treatment influence the development of SaP-derived DNA adducts. Sound data shows
that p53 is up-regulated in response to SPDE-induced DNA damage [124-127].
Additionally, in vitro and in vivo studies report curcumin as an inhibitor of SPDE-DNA
adducts. Topical application of curcumin in mice, for example, inhibits SaP conversion
into SPDE [128]. Another study reports that curcumin inhibits SaP-induced DNA strand
breaks in human peripheral blood lymphocyte cells [6]. However, little is known whether
curcumin has an influence on p53 and p53-mediated responses in response to SPDEderived DNA adducts rather than SaP-derived DNA adducts.
A possible connection between curcumin and p53-mediated responses in the
reduction of SPDE-induced DNA damage has been investigated including the ability of
curcumin to augment p53-dependent apoptosis [129]. Yet, the influence of curcumin on
p53 expression and function is quite controversial as a recent report suggests that
curcumin may in fact inhibit rather than stimulate p53 activity [130;131].
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Although an overwhelming number of reports indicate that curcumin exerts a
protective mechanism in response to BPDE-induced DNA damage, my study shows for
the first time a link between curcumin pretreatment and p53-expression in reducing
BPDE-DNA adducts. In particular, curcumin significantly reduced BPDE-DNA adducts in
a p53-dependent manner in A549 lung epithelial cells (Figure 11 and Table 1). BPDEDNA adducts were significantly higher in A549/E6 (p53-) cells and not changed by
curcumin pretreatment. It should be noted that relative amounts of BPDE-DNA adducts
were assessed on different membranes depending on the BPDE concentration used.
Thus, relative BPDE-DNA adducts cannot be compared between different BPDE
concentration groups. This study, consistent with others, shows that p53 is up-regulated
in a concentration-dependent manner in response to BPDE-induced DNA damage in
A549/LXSN cells (Figure 12 and 14). Curcumin pretreatment increased p53 upregulation in p53-expressing cells. In contrast, p53 was absent in A549/E6 cells in
response to curcumin and BPDE treatment. Therefore the results of this chapter
demonstrate that curcumin reduces BPDE-induced damage by increasing p53.
Activated p53 signals a number of cellular responses including DNA repair
[97;132]. While I showed that BPDE-DNA adduct formation was p53-dependent and
significantly reduced in the presence of curcumin in p53-expressing cells, the overall
removal rate of BPDE-DNA adducts was dependent of p53 expression not curcumin
pretreatment (Figure 17). Additionally, BPDE-DNA adducts in p53-deficient cells
increased in a time-dependent manner. This observation is consistent with other studies
which also show an increase of BPDE-DNA adducts over time in p53-deficient cells.
BPDE is a hydrophobiC compound which readily lodges in the cell membrane [133;134].
The absence of p53, and thus lack of protective mechanism, prevents removal of BPDEDNA adducts. Inefficient removal of BPDE therefore increases the formation of BPDEDNA adducts over time as BPDE leaves the lipid depots.
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Recognition of DNA adducts by XPC and DDB2 is the rate limiting step which
initiates the GGR pathway. While an overwhelming amount of data shows p53 regulates
basal and inducible expression of XPC and DDB2, these studies were implemented in
fibroblasts [59;97-99]. My results, on the other hand, revealed that XPC and DDB2 are
not induced by p53 expression in A549 cells (Figures 12 and 14). Curcumin
pretreatment enhanced XPC, but not DDB2, expression in a p53-independent manner.
Yet, XPC and DDB21eveis were not induced by BPDE treatment. Contrasting studies
revealed that the basal and inducible expressions of XPC and DDB2 are not only
regulated by p53 [135]. Recent studies have shown that human keratinocytes, unlike
fibroblasts, do not require p53 to maintain basal levels of XPC and DDB2 [136-138]. In
fact it is suggested that p63, an isoform of p53, modulates repair of DNA damage in
human keratinocytes [138; 139]. Also, strong evidence for the functional interaction
between DDB2 and the transcription factor E2F1 , a proliferative marker in many
cancers, has been implicated in cancer cell growth [136;140]. Because I used epithelial
cells rather than fibroblasts, possible cross talk between E2F1 as well as modulation by
p53 isoforms like p63 could explain the presence, but not induced form of DDB2.
Therefore XPC and DDB2 in A549 cells may be regulated by multiple proteins other than
p53.
Nevertheless, the results from this study show that curcumin significantly
reduced BPDE-DNA adducts in a p53-dependent; yet, XPC and DDB2 are not induced
in response to BPDE-induced DNA damage (Figures 12 and 14). Thus, p53 may
regulate other steps of the NER system besides DNA damage recognition. Studies show
p53 physically binds to the TFIIH helicase subunits, XPB and XPD [123;141 ;142]. XPB
and XPD are important proteins which unwind the damage DNA complex to expose
damage thereby creating the substrate for cleavage (Figure 6). It is also suggested that
p53 may function as a chromatin accessibility factor in NER [143]. That is, in response to
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DNA damage, p53 signals chromatin relaxation which subsequently extends over the
entire genome. As a result, global chromatin relaxation leads to bulky DNA damage
recognition over the entire genome by the GGR system. It is unclear whether curcumin
influences the activity of TFIIH helicase or the chromatin accessibility factor. On the
basis of the present findings, a possible mechanism by which curcumin reduces BPDEDNA adducts is summarized in Figure 22.
The conjugation of BPDE to GSH by GST is believed to be the most important
enzymatic pathway to inactivate BPDE [61 ;62; 107]. Studies have suggested that GST
interacts with p53 expression to provide a protective mechanism against BPDE-induced
DNA damage [64;109]. Furthermore, it has been shown that administration of curcumin
may inhibit BaP-induced forestomach tumorigenesis in mice by increasing hepatic GST
activity [5]. My study, however, shows that GST activity along with GSTP and GSH
levels were not influenced by curcumin pretreatment or p53 expression in response to
BPDE-induced DNA damage (Figures 17 through 21). Therefore curcumin pretreatment
does not reduce BPDE-DNA adducts in a p53-dependent manner by modulating BPDE
inactivation through glutathionylation. While the GSH system is the most prominent
pathway to inactivate BPDE-induced DNA damage, other phase II detoxifying systems
including NADPH:quione reductase may be involved.
Possible direct interaction between curcumin and BPDE may also reduce levels
of BPDE-DNA adducts. Computational studies show the naturally occurring compound,
ellagic acid, also prevents BPDE-DNA adducts [144;145]. Ellagic acid, like curcumin, is a
polyphenol (Figure 23). Huetz et. aI, among others, demonstrated that the phenolic OH
group of ellagic acid forms a chemical bond with the epoxy ring of BPDE [81;146-148].
Thus ellagic acid acts as a scavenger by physically binding to BPDE. Studies also show
other compounds including thiol-containing purine analogues covalently bind to BPDE
[133;134]. While both curcumin and ellagic acid are characterized as polyphenols only
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Figure 22. Possible mechanism by which curcumin reduces BPDE-DNA adducts.
Curcumin pretreatment in response to BPDE-induced DNA damage increases p53
levels. As a result, BPDE-DNA adducts are removed. Because XPC and DDB2 levels
did not change with curcumin pretreatment and p53 expression , this figure speculates
that other p53-mediated DNA repair proteins are involved. Namely, p53 may activate
helicases XPB and XPD of the NER system as well as chromatin assembly factor in
order to repair BPDE-DNA adducts in a p53-dependent manner.
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Figure 23. Structures of curcumin (A) and ellagic acid (8). (A) Adapted from "Curcumin,
resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary
compounds," by K. 8isht, 2010, Toxicology278(1), p. 88-100. (8) Adapted from
"Reaction between ellagic acid and an ultimate carcinogen," by P. Huetz, 2005,

J.Chem.lnf.Model, v. 45, no. 6, p. 1564-1570.
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ellagic acid possesses cis diols. Therefore, curcumin may in fact change its
conformation such that its phenol groups are positioned like cis diols. As a result, the
different conformation of curcumin may allow it to act as a scavenger and bind to BPDE.
To date there is no evidence which shows whether curcumin forms a chemical bond with
BPDE.
In conclusion, this chapter shows that curcumin reduces BPDE-DNA adduct
formation in a p53 dependent manner. However curcumin does not impact XPC, DDB2,
or the GSH system in order to decrease BPDE-DNA adducts in a p53-dependent
manner. Additionally, curcumin pretreatment did not influence how rapid BPDE-DNA
adducts are removed. Therefore, further studies are needed to determine the exact
mechanism of action by which curcumin prevents BPDE-DNA adducts in a p53dependent manner.
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CHAPTER III

CURCUMIN AFFECTS CELL CYCLE ARREST AND APOPTOSIS IN HUMAN LUNG
EPITHELIAL CELLS IN RESPONSE TO BPDE-INDUCED DNA DAMAGE
Introduction
Humans are exposed to a host of environmental carcinogens such as polycyclic
aromatic hydrocarbons (PAHs). One of the most potent PAHs is benzo[a]pyrene (BaP)
[149]. BaP, a PAH well characterized in both human and animal model systems, is best
described as an ubiquitous carcinogen produced by incomplete combustion of organic
matter [37]. While BaP is converted into a number of metabolites, 7 R, 8S-dihydroxy-9S,
10R-epoxy-7, 8, 9, 10-tetrahydrobenzb[a]pyrene (BPDE) is the most carcinogenic
derivative [150;151]. Characterized by a bay region which promotes its highly reactive
electrophilic activity, BPDE readily binds to nucleophiles [152]. BPDE, however, primarily
attaches to the exocyclic amino group of guanine bases bulky adducts on DNA (N 2 _
BPDE-dG). When BPDE-DNA adducts are not repaired, detrimental effects such as
mutations may occur which lead to cancer.
Activation and stabilization of the suppressor protein p53 is an important event in
response to DNA damage [153;154]. In unstressed cells, p53 protein levels are low due
to HDM2-mediated ubiquitinylation and degradation [42]. As a result, cyclins and cyclin
dependent kinase (CDKs) interact with each other to induce phosphorylation of
retinoblastoma protein (pRb). Phosphorylated pRb dissociates and activates E2F1. In
turn, activated E2F1 induces the expression of genes such as cyclins E and A which
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promote cell cycle progression. However, when DNA damage is sensed, protein kinases
ATM (ataxia telangiectasia, mutated)and ATR (ATM- and Rad3-related) are activated to
phosphorylate p53 at Ser15 [155]. In addition, ATM and ATR can indirectly
phosphorylate p53 at Ser20 by activating checkpoint kinases CHK2 and CHK1,
respectively [156]. Phosphorylation of p53 at Ser15 and Ser20 inhibits the interaction
between p53 and HDM2, resulting in p53 stabilization [157;158]. P53 stabilization slows
p53 to be further modified and activated. Depending on the severity and duration of
damage, activated p53 signals several cellular responses including cell cycle arrest. As
a result, induction of cell cycle arrest will allow sufficient time for repair of BPDE-DNA
adducts.
Up-regulation of the cyclin dependent kinase inhibitor (CDKI) CDKN1 A (also
known as p21wAF1/CIP1) in response to p53 activation is a common mechanism that
signals cell cycle arrest. CDKN1 A expression prevents the interaction between cyclinCDK complexes and subsequent pRb phosphorylation [159]. As a result,
hypophosphorylated pRb remains bound to and inactivates E2F, thereby promoting cell
cycle arrest until DNA is repaired. In addition to signaling a p53-mediated cell cycle
arrest, it is well established that BPDE treatment causes S-phase arrest in p53-null cells.
BPDE-DNA adducts interfere with DNA replication which are sensed by ATR [155;160].
Consequently, CHK1 is phosphorylated and activated at Ser317 and Ser345,
phosphatase Cdc25A is targeted for degradation. As a result, lack of Cdc25A expression
inhibits dephosphorylation of the cyclin ElA-cdk2 complex and S phase arrest occurs
[122]. Collectively, activated p53 and CHK1 signal cell cycle arrest which allows time for
DNA to be repaired. However, physiological exposure to BPDE is relatively low and fails
to signal cell cycle arrest. Thus unrepaired DNA damage leads to an increased likelihood
of mutations which ultimately result in cancer.
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Epidemiological studies indicate a low incidence of certain cancers, such as lung
cancer, in the Eastern World compared to Western countries [72]. Researchers
speculate the disparity between certain cancers could be due to lifestyle, including diet.
Among the dietary agents linked to this disparity include curcumin. Curcumin is a
polyphenolic compound from the rhizome plant Curcuma tonga (Linn). This agent is
heavily consumed in Asia, an area which exhibits a low incidence of cancer
[69;72;84; 161; 162]. Curcumin is suggested to be a potent inhibitor of DNA damage and
tumor development [83;87;163]. Numerous independent studies have indicated that
curcumin influences the expression of genes responsible for cell cycle progression.
Namely, curcumin treatment in a variety of cancer cells up-regulated p53, CDKN1 A, and
p27 and down-regulate cyclins B, D, and E [115;164;165]. Additionally, pancreatic
cancer cells treated curcumin resulted inactivation of the ATM/Chk1 pathway followed by
cell cycle arrest and apoptosis. Curcumin has also been shown to inhibit chemical
carcinogenesis by enhancing phase II metabolizing enzymes [100-102].
Although curcumin has been shown to decrease BaP-derived DNA adduct
formation as well as induce p53, little evidence is available whether curcumin may
induce cell cycle checkpoints in order to allow sufficient time for repair of BPDE-induced
DNA damage. Therefore I investigated if curcumin regulates cell cycle arrest in response
to BPDE-induced DNA damage independent of p53 expression.
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Materials and Methods

Cell cultures, curcumin treatment, and BPDE exposure
A549 cells were grown, treated with curcumin, and exposed to BPDE as
previously described in Chapter II of this dissertation.

Western Blot
Protein Iysates from cells were collected as previously described in Chapter II of
this dissertation. Membranes were incubated with the following primary antibodies and
dilutions as described by the manufacturer:anti-p53 monoclonal mouse antibody
(NeoMarkers, Cat# MS-187-P) (1:1000); anti-phospho-p53 Ser15 mouse polyclonal
antibody (Cell Signaling Technology, Cat#9284) (1 :500); anti-caspase-3 rabbit polyclonal
antibody (Cell Signaling Technology, Cat#9662) (1: 1000); anti-phospho-Rb Ser807/811
rabbit polyclonal antibody (Cell Signaling Technology, Cat# 9308) (1:1000); anti-cyclin A
rabbit polyclonal antibody (Cell Signaling Technology, Cat # 4656) (1 :1000); antiCDKN1A rabbit polyclonal antibody (also known as anti-p21) (Santa Cruz Cat # sc756)
(1 :1000); or anti-cyclin E mouse monoclonal antibody (Cell Signaling Technology, Cat#
4132) (1 :2000). Mouse antibodies were bound by rabbit anti-mouse IgG conjugated to
horseradish peroxidase. Rabbit antibodies were bound by goat anti-rabbit IgG
conjugated to horseradish peroxidase for detection. Detection of GAPDH (Abcam, Cat#
ab9484) (1:10.000) or J3-actin (Abcam, Cat# ab8227) (1:10,000) served as the loading
controls.

Flow cytometry
Cells were plated in 10-cm dishes and treated with curcumin followed by BPDE
as previously described in Chapter II. A549 cells were immediately collected (0 h), or
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refed with fresh BPDE-free media for 6, 12, 16, or 24 hours. Upon collection, the cells
were washed with 5 mL 1x PBS and 5 mL 1x PBSE (1 x PBS containing 5mM EDTA).
Cells were harvested by trypsinization with 1.5 mL 1x trypsin (Invitrogen, Cat#15400054). Trypsinized cells were collected with media, and briefly centrifuged (15,000 x g) at
room temperature. The supernatant was removed, the pellet was washed with 3 mL
1xPBS, and fixed in 70% ethanol (7 parts 100% ethanol and 3 parts 1x PBS) overnight
at 4°C. The next day the cells were centrifuged at 15,000 x gto pellet. Then the cells
were resuspsended in 1X PBS and incubated at 37°C with RNase A (100 j.Jg/mL) for 3 h.
The cells were stained with propidium iodide buffer (propidium iodide, 10 Jlg/mL; Tween20, 0.5%; RNase A, 0.1 % in PBS) and incubated an additional 30 min in the dark at

3rC. The fluorescence from stained samples was collected on channel 2 (FL2; 585142
nm) using linear amplification. A minimum of 20,000 events/sample were analyzed using
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). Electronic gating was set
up to remove any cell debris, cell doublets and cell clumps. The intensity of the cell's
fluorescence was proportional to the amount of DNA in the cell. After standardization for
each cell line using Cell Quest software (Becton Dickerson, Franklin Lakes, NJ), cells
were assigned to different cell cycle compartments based on DNA content using FloJo
software (Tree Star, Inc., Ashland, OR).
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Results
Curcumin enhances p53, p53S15 and CDKN1A induction in response to BPDEinduced DNA damage
Curcumin treatment has been shown to up-regulate p53. However, it is unclear if
curcumin may increase p53 expression in response to BPDE-induced DNA damage.
Therefore, we used Western blotting analysis to determine whether curcumin may
influence p53 and p53-regulated cell cycle progression proteins. Figure 24A shows that
p53, p53S15, and CDKN1A increased in a concentration- and time-dependent manner in
A549/LXSN (p53+). P53, p53S15, and CDKN1A were not present in A549/E6 (p53-)
cells (Figure 24B). Curcumin strongly induced p53, p53S15, and CDKN1A levels in p53+
cells in a concentration and time-dependent manner. Specifically, curcumin increased
p53, p53S15, and CDKN1A in p53+ cells 24 hours after lower BPDE concentrations
(::0100 nM). Therefore these results indicate that CDKN1 A is regulated by p53 expression
and curcumin enhanced the stabilization and subsequent up-regulation of CDKN1A with
lower BPDE concentrations.

P-pRbS807/811 decreases in a p53-independent manner in response to BPDEinduced DNA damage
Normally in unstressed cells, cyclins and CDKs (cyclin-CDKs) interact which
subsequently phosphorylate pRb. Phosphorylation of pRb causes pRb to dissociate from
E2F1. E2F1 , in turn, is activated and signals the upregulation of genes responsible for
cell cycle progression (Figure 5). However, when CDKN1 A is present, the cyclin-CDK
complex is inhibited, thereby preventing cell cycle progression. Because I found in
Figure 24A that curcumin up-regulates CDKN1A in p53-expressing cells in response to
BPDE-induced DNA damage, I investigated if phosphorylated pRb (P-pRb) is downregulated. Specifically I examined pRb phosphorylated at Ser807/811.
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Figure 24. Curcumin enhances p53 and CDKN1 A induction in response to BPDEinduced damage. A549/LXSN (p53+) (A) and A549/E6 (p53-) (B) were treated with

or

without 2.5 IJM curcumin for 24 h. Next the cells were treated with 0, 50, 100 or 300 nM
BPDE for 1 h and either harvested immediately (0 h) or 24 h. Twenty micrograms of
protein was loaded for Western blot analysis. The expression of p53, p5315 and
CDKN1A were induced. P-pRbS807/811 decreased in response to BPDE-induced
damage in p53+ cells. Pretreatment with curcumin increased the expression of p53,
p5315 and CDKN1 A, and decreased pRbS807/811 with lower BPDE concentrations.
Data shown is a representative from three independent experiments.
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Unexpectedly, pRb phosphorylated at serines 807 and 811 (P-pRbS807/811)
was affected in both cell lines. Figure 24A shows that levels of P-pRbS807/811
decreased in a concentration- and time-dependent manner in pS3-expressing
AS49/LXSN cells after BPDE treatment. Curcumin pretreatment further reduced levels of
P-pRbS807/811. P-pRbS807/811 in BPDE treated AS49/E6 (pS3-) cells also decreased
in a concentration- and time-dependent manner. Curcumin pretreatment in AS49/E6
cells enhanced P-pRbS807/811 levels. Taken together, these results suggest that
curcumin pretreatment influences cell cycle arrest independent of pS3 expression in
response to BPDE-induced DNA damage.

S-phase accumulation in response to BPDE-induced DNA damage is altered with
curcumin pretreatment
Flow cytomtery was used to determine the exact location of cell cycle arrest in
response to BPDE-induced DNA damage. PS3-expressing (Figure 2S) or pS3-deficient
(Figure 26) cells were pretreated with 0 (A through C) or 2.S IJM curcumin (0 through F)
for 24 hours. Cells were then exposed to SO (A and D), 100 (B and E), or 300 nM BPDE
(C and F) for 1 hour. AS49 cells were collected at 0 (immediately after BPDE treatment),
6, 12, 16, or 24 hour after BPDE treatment.
AS49/LXSN cells exposed to SO, 100, or 300 nM BPDE accumulated in S phase
(Figure 2S). Thus, S phase arrest occurs in response to BPDE-induced DNA damage in
pS3+ cells. PS3+ cells escaped S phase arrest at different time pOints, depending on
BPDE concentration. AS49/LXSN cells treated with ::;;1 OOnM BPDE escaped S phase
arrest after 12 hours (Figures 2SA, B, D,and E). On the other hand, pS3+ cells treated
with 300 nM BPDE did not escape S phase arrest until at least 16 hours after BPDE
treatment (Figure 2SC). Curcumin pretreatment only affected AS49/LXSN cells treated
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Figure 25. P53-expressing A549/LSXN cells transiently arrest in S-phase in response to
BPDE-induced damage. A549/LXSN (p53+) cells were treated with 0 (A-C) or 2.5 IJM
curcumin (D-F) for 24 h. Then the cells were exposed to 50 (A and D), 100 (B and E), or
300 nM BPDE (C and F) for 1 h, harvested immediately (0), 6, 12, 16, or 24 h after
exposure. P53+ cells were stained with propidium iodide and DNA content was analyzed
using flow cytometry as described in methods. Data presented as mean
three independent experiments.
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Figure 26. P53-deficient A549/E6 cells arrest in S phase, but never escape with lower
BPDE concentrations. A549/E6 (p53-) cells were treated without (A-C) or with 2.5 IJM
curcumin (D-F) for 24 h. Then the cells were exposed to 50 (A and D), 100 (B and E), or
300 nM BPDE (C and F) for 1 h, harvested immediately (0 h), 6, 12, 16, or 24 h after
exposure. P53- cells were stained with propidium iodide and DNA content was analyzed
using flow cytometry as described in methods. Data presented as mean ± STDEV of
three independent experiments.
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with 300 nM BPDE (Figure 25F). Specifically, p53+ cells pretreated with curcumin
followed by 300 nM BPDE escaped S phase arrest after 12 hours.
Curcumin did not have an influence cell cycle progression in p53+ cells treated at
50 and 100 nM BPDE. Exposure to BPDE and curcumin also affected A549/E6 (p53-)
cells (Figure 26). P53- cells accumulated in S phase around 12 and 16 hours after 50
(Figure 26A) and 100 nM (Figure 26B) BPDE treatment, respectively. P53- cells treated
with 300 nM stagnant in S phase (Figure 26C). Curcumin pretreated A549/E6 cells
accumulated in S phase 6 hours after 50 and 100 nM BPDE (25D and 25E,
respectively). Curcumin pretreated p53- cells gradually accumulated in G1 in response
to 300 nM BPDE (Figure 26F).

P53-expressing cells accumulate primarily within S-phase in response to BPDEinduced DNA damage
S-phase is characterized by the expression of two cyclins: cyclin E and cyclin A.
Cyclin E regulates G1-to-S transition, while cyclin A is responsible for progression
through the S-phase. Cyclins E and A were therefore examined in A549 cells treated
with 300 nM BPDE to determine where cells arrest when treated with BPDE (Figure 27).
The results show that cyclin A, not cyclin E, increased in a time-dependent manner
following 300 nM BPDE treatment in p53-expressing cells (Figure 27A). Curcumin
pretreatment in p53+ cells increased cyclin A 12 hours rather than 24 hours after 300 nM
BPDE treatment. Cyclins E and A, however, were not affected by curcumin and/or BPDE
treatment in p53-deficient cells (Figure 27B). Therefore the results from the Western blot
support the flow cytometry data of S phase arrest in p53+ cells.
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Figure 27. Levels of cyclin A and E in response to curcumin pretreatment and exposure

to BPDE. A549/LXSN (p53+) (A) and A549/E6 (p53-) (B) were treated with or without 2.5
IJM curcumin for 24 h. Next the cells were treated with 300 nM BPDE for 1 hand
harvested immediately (0 h), and 6, 12, 16 or 24 h later. Twenty micrograms of protein
were loaded for Western blot analysis. Levels of cyclin A, but not cyclin E, increased in a
time-dependent manner in p53+ cells . Data shown is a representative from two
independent experiments.
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pCHK1 Ser345 is active in p53- cells in response to BPDE treatment
Phosphorylated CHK1 at Ser317 and Ser345 (pCHK1 S317 and pCHK1 Ser345,
respectively) signal S phase arrest in response to DNA damage. Therefore we used
Western blot to confirm our flow cytometry data which indicated that BPDE-induced DNA
damage signaled S phase arrest in p53- cells (Figures 28). P53-expressing or p53deficient A549 cells were either pretreated with or without curcumin for 24 h. Cells were
then exposed to 300 nM BPDE for 1 hour. A549 cells were collected at different time
points between 0 (immediately after BPDE treatment) and 24 hours. As shown in Figure
26, pCHK1S345 was higher in A549/E6 (p53-) cells than A549/LXSN (p53+) cells in
response to 300 nM BPDE. pCHK1 Ser345 increased between 0 and 16 hours after 300
nM BPDE in both cell lines with or without curcumin pretreatment. Curcumin
pretreatment significantly increased pCHK1 Ser345 16 hours after BPDE exposure.
Notably, an additional band, which has appeared in other studies [122], was present. I
speculate that the additional band is phosphorylation of CHK1 at Ser317 and Ser345.

High BPDE concentrations induce apoptosis in p53-deficient cells
Based on the evidence that p53- cells began to accumulate in G1 phase in
response to 300 nM BPDE, I studied whether BPDE and curcumin induced apoptosis
over time. Therefore I collected p53- cells at 36, 48, and 72 hours after 300 nM BPDE
(Figure 29) to determine if apoptosis is induced. BPDE treated A549/E6 (p53-) cells
accumulated in the sub-GO/G1 compartment in a time-dependent manner (Figure 29A
and B). Accumulation of cells in sub-GO/G1 compartment indicates apoptosis. Curcumin
pretreatment significantly increased the fraction of p53- cells in sub-GO/G1 compartment
48 h after 300 nM BPDE. Activated caspases further provide evidence that apoptosis is
occurring. Therefore I examined levels of caspase-3 in p53- cells 36, 48 and 72 hours
after 300 nM BPDE treatment (Figure 29C). Figure 29C shows that caspase-3 increased
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Figure 29. Curcumin enhances apoptosis in apoptosis in A549/E6 cells in response to
300 nM BPDE. A549/E6 (p53-) cells were treated with or without 2.5 IJM curcumin for 24
h. Then the cells were exposed to 300 nM BPDE for 1 h, harvested immediately 36 , 48,
or 72 h after exposure. P53- cells were stained with propidium iodide and DNA content
was analyzed using flow cytometry. Figures (A) and (B) represent qualitative and
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analyzed by Western Blot (C) . Data presented in (B) is means ± STDEV of three
independent experiments. Data shown in (C) is a representative from three independent
experiments. * p<0.05 for DMSO vs. curcumin pretreatment at indicated time point.
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in a time-dependent manner in p53- cells.
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Discussion
BaP is an ubiquitous environmental carcinogen that is metabolized into BPDE.
[20;166-168]. BPDE binds and damages DNA. P53 is a key element activated in
response to BPDE-induced DNA damage [124]. P53 signals a host of intracellular
responses including cell cycle arrest. Induced cell cycle arrest is suggested to allow time
for DNA to be repaired. Environmental exposure to BaP and consequently BPDE,
however, fails to activate p53 [95;169]. Curcumin reduces BPDE-DNA adducts and
induces cell cycle arrest [70;170]. Yet, its exact role in cell cycle progression in response
to BPDE-induced DNA damage is unclear.
In the present study, p53 is up-regulated in response to BPDE-induced DNA
damage (Figure 22). Additionally, independent studies have shown that CDKN1A is
regulated by p53 expression [51 ;171 ;172]. The results presented support these data
which show that p53 levels increase in response to BPDE and CDNK1 A is regulated by
p53 expression (Figure 22). In addition, to our knowledge, I show for the first time that
curcumin further increased p53 up-regUlation as well as CDKN1 A in response to with
lower BPDE concentrations. Therefore curcumin acts as a chemopreventive by
enhancing p53 stabilization. In turn, enhanced p53 stabilization allows increases p53
ability to become activated and subsequently signal ability cell cycle arrest. As a result,
enhanced cell cycle arrest in response to BPDE-induced damage allows time for DNA
repair to occur. Increased levels p53 and p53S15P with lower concentration of BPDE
may be a result of curcumin inducing mild oxidative stress. While curcumin is best
known to possess anti-oxidant properties, studies characterize curcumin as a prooxidant which damages DNA and enhances chromosomal damage. In mouse-rat hybrid
retinal ganglion cell line N18 cells, Comet assay showed that curcumin at doses as low
as 10 IJM led to a longer DNA migration smear. DNA gel electrophoresis also showed
that exposure to 20 IJM curcumin for 24 and 48 h induced DNA damage and
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fragmentation in N18 cells. Therefore, curcumin pretreatment may be inducing slight
oxidative stress in A549 cells to enhance p53 induction in response to BPDE exposure.
P53 activation signals a number of cellular responses including cell cycle arrest.
The induction of the CDKN1A is associated with p53 transactivation. When CDKN1A is
present it inhibits the interaction between cyclins and cyclin dependent kinases (CDKs).
The inhibition of cyclins and CDKs prevents the phosphorylation and subsequent
dissociation of retinoblastoma (pRb) from the transcription factor E2F1 [49]. The data
revealed a concentration-dependent increase in CDKN1A in response to BPDE-induced
damage. On the other hand, protein levels of P-pRbS807/811 decreased in a time- and
concentration-dependent manner in response to BPDE (Figure 22A). When A549/LXSN
(p53+) cells were pretreated with curcumin, CDKN1A further increased while PpRbS807/811 decreased. These results support previous observations obtained by
Aggarwal et al. 2007 which indicate that curcumin enhanced the expression of CDKN1A
in MCF7 breast carcinoma cells [164]. Furthermore, our study showed that cell cycle
progression is inhibited primarily within S phase; pretreatment with curcumin caused
cells to escape S phase arrest much earlier with high BPDE concentrations (> 100 nM)
(Figure 24A). Thus, the data presented showed an enhance increase in p53, p53Ser15,
and CDKN1 A and further decrease in p-pRbS807/811 in p53+ cells pretreated with
curcumin. These data are further supported by flow cytometry data which showed that
p53+ cells arrest in S phase. Taken together, the data presented indicate that curcumin
plays a role in cell cycle progression in p53-expressing cells.
Unexpectedly, levels of P-pRbS807/811 also decreased in A549/E6 (p53-) cells
in a dose dependent manner in response to BPDE exposure (Figure 22B). This was an
interesting finding because we hypothesized that cell cycle progression in the presence
of BPDE should be maintained in the absence of p53 expression. However the data
demonstrated that cell cycle arrest is occurring in response to BPDE in a p5373

independent manner. In support with our results, p53-deficient H1299 lung
carcinoma cells also promoted cell cycle arrest in response to BPDE-induced damage
[122]. Levels of P-pRb807/811 were much higher when A549/E6 cells were pretreated
with curcumin.
The data shows that p53-deficient cells, like p53-expressing cells, arrest in Sphase (Figure 25). The observation of S phase arrest in response to BPDE-induced
DNA damage further support a decrease in P-pRb. However, p53- cells were not cycling
with 300 nM BPDE. Instead, p53- cells were stalled in S-phase as shown in Figure 25.
Halting in S-phase is sometimes referred to as DNA replication stalling. Studies show
that P-Chk1Ser345 is activated in response to DNA replication stalling [122;173]. It is
suggest that inefficient repair of stalled DNA replication results in double strand breaks
which ultimately signals apoptosis [155;156]. The high levels of P-CHK1Ser45 in the
p53-defcieint cells and signaling of apoptosis with 300 nM BPDE, implicates that DNA
replication is stalled. Thus it would be advantageous to determine if double strand
breaks occur in response to 300 nM BPDE. Taken together, the data in Figures 26 and
27 indicate that curcumin may in fact sense the inability the continuous stalled DNA and
signal programmed cell death independent of p53 expression.
Overall, the results presented show that curcumin signals cell cycle arrest and
apoptosis independent of p53 expression. Induction of cell cycle arrest involves different
pathways based on the status of p53. In the presence of p53, CDKN1A is signaled. Yet,
when p53 is absent, CHK1 is activated to signal S phase arrest. Curcumin enhanced
both pathways. Therefore, curcumin may act as a chemopreventive by activating
multiple cell cycle checkpoint mechanism and apoptotic pathways in response to BPDEinduced DNA damage.

74

CHAPTER IV

GENERAL DISCUSSION

Curcumin is a well known chemopreventive agent which acts against
carcinogenesis caused by BPDE-induced DNA damage. Nevertheless, to date it is
unclear how curcumin reduces BPDE-induced DNA damage. This research project
focused on filling this gap in knowledge by investigating whether curcumin plays a role in
p53-mediated cell cycle arrest and DNA repair mechanisms in response to BPDEinduced DNA damage.
In chapter 2, I determined that curcumin does reduce BPDE-DNA adducts in a
p53-dependent manner. Surprisingly, I discovered that neither curcumin pretreatment,
p53 expression nor exposure to BPDE influenced expression of DNA damage
recognition proteins XPC and DDB2 in response to DNA damage. The GSH
detoxification pathway, which is the predominantly inactivation pathway for BPDE, was
also investigated to determine whether it may influence BPDE-DNA adduct levels in our
system. However, I observed that neither curcumin pretreatment, p53 expression, nor
BPDE treatment significant changed GST activity, or GSTP and GSH levels. Therefore
curcumin pretreatment and p53 expression are altering other mechanisms besides DNA
damage recognition and GSH detoxification pathways.
Studies have revealed that XPC and DDB2 are not exclusively regulated by p53
expression [135;138]. In fact, studies show that XPC and DDB21eveis can be regulated
by p53 isoforms, such as p63, based on cell type. Additionally, p53 expression has been

75

shown to regulate other factors involved in DNA repair of BPDE-induced damage.
Namely, p53 is suggested to regulate TFIIH activity and to stimulate the chromatin
assembly factor [123; 142; 143]. TFII H is responsible for unwinding the damaged DNA,
while chromatin assembly factor exposes damaged DNA to DNA repair proteins. Thus,
further studies are needed to investigate not only whether p63 influences XPC and
DDB2 levels in A549 lung epithelial cells, but also if p53 reduces BPDE-DNA adducts by
inducing unwinding of the damaged DNA or activating chromatin assembly factor. Thus,
curcumin pretreatment may have a profound impact on p63 or other NER factors in
order to significantly reduce BPDE-DNA adducts in a p53-dependent manner.
In chapter 3, I observed that p53, p53 phosphorylated at Ser15 (p53S15), and
CDKN1 A are up-regulated in a concentration-dependent manner in response to BPDEinduced damage only in p53-expressing cells. Therefore CDKN1 A is regulated in a p53dependent manner and signals cell cycle arrest in response to BPDE-induced damage in
p53-expressing cells. On the other hand, retinoblastoma protein phosphorylated at
Ser807/811 (pRbS807/811) was down-regulated in both p53-expressing and p53-

deficient cell lines in response to BPDE-induced damage. Thus this BPDE-induced DNA
damage can signal cell cycle arrest independently of p53-expression. Additionally,
curcumin pretreatment affected levels of p53, p53S15, CDKN1A, and pRbS807/811.
Curcumin increased levels of p53, p53S15, and CDKN1A and further decreased
pRbS807/811 in p53 expressing cells with lower BPDE concentrations. While p53,
p53S15, and CDKN1A were absent in p53 deficient cells, curcumin pretreatment
increased pRbS807/811 levels. From these result, it can be concluded that curcumin
influences cell cycle progression in both a p53-depdent and p53-independent manner.
I also determined where cells arrested in response to BPDE-induced damage.
I discovered that BPDE-induced damage signals S-phase arrest in a p53-independnent
manner. While p53-expressing cells escaped S-phase arrest over time, p53-deficient
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cells remained in S-phase arrest and eventually signaled apoptosis. Again, curcumin
pretreatment influenced cell cycle arrest and apoptosis in p53-expressing and p53deficient cells. Signaling of apoptosis and cell cycle arrest in both cell lines in response
to curcumin pretreatment was influenced by concentration and integrity of p53
expression. From and expression p53-expressing and deficient cells arrested in S-phase
in response to BPDE-induced damage. However curcumin pretreatment in both cell lines
affected entering and exiting S phase arrest as well as apoptosis in p53 deficient cells.
Two cyclins are associated with S phase. Cyclin E is responsible for the G1-to-S
transition, whereas cyclin A pushes cells through S phase. With a high BPDE exposure,
I found that in p53-expressing cells cyclin A, but not cyclin E, increased over time. Thus
in response to a high concentration of BPDE, p53-expressing cells arrested within S
phase. Cyclins A and E did not change in p53-deficient cells with a high BPDE exposure.
Taken together, this dissertation shows that curcumin exerts it chemopreventive
properties by regulating a host of mechanisms in response to BPDE-induced damage.
Curcumin significantly reduced BPDE-DNA adducts in a p53-dependent manner.
However, the expected p53 target genes, XPC and DDB2, were not regulated by p53
expression and curcumin pretreatment. Therefore, future studies are needed to
determine whether curcumin influences other p53-mediated DNA repair proteins in
response to BPDE. In response to BPDE-induced damage, curcumin has an effect on Sphase progression in a p53-independent manner. While curcumin signaled the p53mediated pathway in p53-expressing cells in response to BPDE with lower BPDE
concentrations, curcumin also activated the ATRlCHK1 pathway in p53-deficient cells.
Curcumin signaled p53-independent apoptosis much earlier. Thus activation of
apoptosis in curcumin pretreated p53-deficient cells disposes of DNA damage much
earlier. Overall, curcumin is an important chemopreventive agent that plays a protective
role against carcinogenesis caused by BPDE-induced DNA damage.
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CHAPTER V

FUTURE DIRECTIONS

In chapter 3, it was determined that curcumin reduces BPDE-DNA adduct
formation in a p53-dependent manner. However curcumin pretreatment did not influence
the rate of DNA repair, XPC, DDB2, or the GSH system in order to decrease BPDE-DNA
adducts in a p53-dependent manner. I speculate that the presence of p53 may playa
role in either: (1) up-regulating other DNA repair proteins or (2) producing curcumin byproducts which prevent BPDE-DNA adducts.
TFIH helicase subunits, XPB and XPD are needed to unwind the damage DNA
complex to expose damage thereby creating the substrate for cleavage (Figure 6). If
XPB and XPD were not present damage would not be recognized for cleavage. Several
reports show p53 physically binds to the TFIIH helicase subunits, XPB and XPD
[123; 141; 142]. Therefore, it would be advantageous to determine whether curcumin
pretreatment up-regulates mRNA and protein levels of XPB and XPD in a p53dependent manner immediately after BPDE exposure. Additionally, p53 is suggested to
function as a chromatin accessibility factor in NER [143]. Therefore in the presence of
DNA damage, p53 signals chromatin relaxation which subsequently extends over the
entire genome. Hence, global chromatin relaxation leads to bulky DNA damage
recognition over the entire genome by the GGR system. Determining whether curcumin
influences the activity chromatin accessibility factor could also explain why BPDE-DNA
adducts are lower in p53-expressing cells.
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Curcumin is a very stable compound in cell culture containing 10% fetal calf
serum and in human blood. Less than 20% of curcumin is decomposed within 1 h, and
after incubation for 8 h, about 50% of curcumin remains in cell culture or human blood.
Over time, curcumin is degraded into trans-6-(4'-hydoxy-3'-methoxy-phenyl)-2,4-dioxo-5hexenal, vanillin, ferulic acid, and feruloylmethane. Degradation products of curcumin
have been reported to inhibit mutagenesis. Specifically, vanillin is suggested to act as an
antimutagen by modifying DNA replication and DNA repair systems after cellular DNA
damage. Besides degrading curcumin, commercial curcumin contains three major
curcuminoids (curcumin, demethoxycurcumin, and bisdemethoxycurcumin). It was found
that the highest antioxidant activity was obtained when the phenolic group was sterically
hindered by the introduction of two methyl groups at the othro position. The phenolic
group is essential for the free-radical scavenging activity, and the presence of the
methoxy group further increases the activity. Therefore, future NMR spectroscopy
studies should be implemented to determine whether curcumin or its metabolized and
degraded derivatives form adducts with BPDE. In addition, HPLC may be used to
determine whether p53 expression plays a role in the production of curcumin derivatives.
By investigating other p53-mediated DNA repair proteins as well as whether p53
expression plays a role in the production of curcumin derivatives, a better understanding
will be gained. This insight will help explain why curcumin significantly reduces BPDEDNA adduct formation in a p53-dependent manner.
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APPENDIX
List of Abbreviations
ATM

ataxia telangiectasia, mutated

ATR

A TR, ATM- and Rad3-related

AP

alkaline phosphatase

BaP

benzo( a)pyrene

BPDE

7 R,8S-dihydroxy-9S, 1OR-epoxy-7,8,9, 10tetrahydrobenzo[a]pyrene

CDK

cyclin dependent kinase

CDKI

cyclin dependent kinase inhibitor

CDKN1A

cyclin dependent kinase inhibitor 1A (also known as p21cIPIWAF1)

CHK1

checkpoint kinase 1

CHK2

checkpoint kinase

DDB1

DNA damage binding protein 1

DDB2

DNA damage binding protein 2

DMEM

DulbeccoNogt modified Eagle's minimal essential medium

DMSO

dimethyl sulfoxide

ECF

enhanced chemifluorescence

ECl

enhanced chemiluminescence

EDTA

ethylene diamine tetraacetic acid

GADD45

Growth arrest and DNA damage protein 45

GAPDH

glyceradehyde-3-phosphate dehydrogenase

GGR

Global genomic repair
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GSH

glutathione

GST

Glutathione-(S)-transferase

GSTA

Glutathione-(S)-transferase alpha

GSTM

Glutathione-(S)-transferase mu

GSTP

Glutathione-(S)-transferase pi

HOM2

human double minute gene 2

HPV

human papillomavirus

HRP

horse radish peroxidase

MOM2

mouse double minute gene 2

MRP

multidrug resistance protein

NaCI

sodium chloride

NER

nucleotide excision repair

PAH

polycyclic aromatic hydrocarbon

PBS

phosphate buffered saline

Phospho-pRb

phosphorylated retinoblastoma protein

PMSF

phenylmethylsulphonylfluoride

pRb

retinoblastoma protein

Rb

retinoblastoma

RNase A

ribonuclease A

SOS

sodium dodecyl sulfate

SOS-PAGE

sodium dodecyl sulfate-polyacrylamide gel electrophoresis

Ser

serine

TBST

Tris buffered saline with Tween-20

TCR

transcription couple repair

TFIIH

transcription factor II group H

TE

Tris-ethylene diamine tetraacetic acid
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UV

ultraviolet

XPB

Xeroderma pigmentosum group B

XPD

Xeroderma pigmentosum group D

XPC

Xeroderma pigmentosum group C
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